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ABSTRACT 
Epidemiological and experimental studies suggest that changes in gut microbial 
balance are associated with increases in the prevalence of allergic diseases. For 
prevention and treatment of allergic diseases, probiotic bacteria are candidate agents. 
Probiotics are proposed to provide beneficial immunoregulatory signals which aid in 
oral tolerance achievement and alleviation of symptoms of allergic diseases. 
Previous studies have demonstrated their positive clinical effects on the prevention 
and treatment of atopic diseases, but immunological effects of probiotic bacteria are 
poorly known. 
 
The present study evaluates both the immunological mechanisms of probiotic bacteria 
in infants with allergic diseases and their preventive aspect among infants prone to 
allergy. Furthermore, the purpose of the study was to characterise the immunological 
features of cord blood mononuclear cells (CBMCs) in infants at high genetic risk for 
allergic diseases, and to investigate whether the pattern of immune response in 
CBMCs is associated with allergic diseases and IgE-sensitization at age two. 
 
GATA-3 expression (p = 0.03), interleukin (IL) -2 (p = 0.026), and IL-5 (p = 0.013) 
secretion of OKT3/anti-CD28-stimulated CBMCs were higher in IgE-sensitized 
infants at age 2 than in non-allergic, non-sensitized infants. Secretion of IFN-γ by 
OKT3/anti-CD28-stimulated PBMCs in vitro was significantly lower in infants with 
cow’s milk allergy (CMA) than in non-CMA infants (p = 0.016), and decreased 
IFN-γ secretion of PBMCs occurred in infants with IgE-associated CMA when 
compared with the    non-CMA infants with an IgE association (any specific IgE 
concentration > 0.7 kU/l or a positive skin prick test to any antigen tested) (p = 
0.001). PBMCs of infants with non-IgE-associated CMA secreted less IL-4 and IL-5 
than did infants with   IgE-associated CMA (p = 0.002, and p= 0.004, respectively). 
  
Lactobacillus GG (LGG) treatment increased secretion of IFN-γ by PBMCs in vitro 
in infants with CMA (p = 0.006) and in infants with IgE-associated eczema (p = 
0.017), when compared to levels in the placebo group. A probiotic mixture, 
however, led to increased secretion of IL-4 by PBMCs in vitro in infants with CMA 
(p = 0.028), when compared with placebo-group levels. The Lactobacillus GG 
treatment induced higher plasma C-reactive protein (CRP) (p = 0.021) and IL-6 (p = 
0.036) levels in infants with IgE-associated eczema than in the placebo group. The 
probiotic mixture induced higher plasma IL-10 levels in infants with eczema   (p = 
0.016): In such infants, post-treatment IL-10 levels were higher in the LGG and 
probiotic mixture groups than in the placebo group (p = 0.046 and p = 0.039). In the 
prevention study of allergic diseases, the infants receiving the probiotic mixture had 
higher plasma levels of CRP (p = 0.008), total IgA (p = 0.016), total IgE (p = 0.047), 
and IL-10    (p = 0.002) than did infants in the placebo group. Increased CRP level at 
age 6 months was associated with a decreased risk for eczema at age 2 years not 
only in the infants who received probiotics but also in the placebo group (OR 0.4 
[95% CI 0.17 to 0.94], p = 0.034 for the whole study group). No association 
appeared with IgE sensitization. 
 
In conclusion, the priming of the GATA-3 and IL-5 pathway can occur in utero, and 
a primary feature of T-cells predisposing to IgE-sensitization seems to directly 
favour Th2 deviation. The Th1/Th2 type cytokine balance seems to differ in IgE-
associated and non-IgE-associated CMA. Lactobacillus GG treatment induced 
increased plasma levels of CRP and IL-6 in infants with IgE-associated eczema, 
suggesting an activation of innate immunity. The probiotic mixture treatment 
therefore raised plasma IL-10 levels, implying that the immune response induced by 
probiotics is strain-specific. In addition, differing immunological responses after 
probiotic supplementation occurred in infants with differing clinical outcomes, 
which reflects the fact that effects of probiotic bacteria are modulated by the host. 
The probiotic mixture, when given to allergy-prone infants, induced inflammation, 
detected as increased plasma CRP levels, which at age 6 months was associated with 
decreased risk for eczema at age 2. The CRP-associated decrease in risk for eczema 
was not restricted to probiotic use, suggesting that low-grade inflammation may 
control the tolerance achievement and protect from eczema. The probiotic-induced 
response in infants was characterized by their higher plasma IL-10, total IgE, and 
CRP levels, without induction of an allergen-specific IgE response. In this respect, 
the probiotic bacteria in infancy appear to induce protective immune profiles that are 
characteristic for chronic low-grade inflammation. 
Keywords: cord blood; eczema; probiotic; T-cell; IgE-sensitization 
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TIIVISTELMÄ 
Epidemiologisten ja kokeellisten tutkimusten perusteella allergisten tautien esiinty-
vyyden lisääntyminen liittyy suoliston mikrobitasapainon muutoksiin.  Probioottiset 
bakteerivalmisteet ovat tämän vuoksi kiinnostava mahdollisuus allergioiden hoidos-
sa ja ennaltaehkäisyssä. Probioottiset bakteerit saattavat tuottaa elimistölle hyödylli-
siä immunoregulatorisia signaaleja, jotka auttavat oraalisen toleranssin saavuttami-
sessa ja vähentävät allergisia oireita. Aiempien tutkimusten mukaan probioottival-
misteilla on positiivisia vaikutuksia allergioiden hoidossa ja ennaltaehkäisyssä, mut-
ta niiden immunologiset vaikutusmekanismit ovat vielä suurelta osin selvittämättä. 
Tämän tutkimuksen tarkoituksena oli selvittää probioottien immunologisia vaiku-
tusmekanismeja lasten allergian hoidossa ja ennaltaehkäisyssä korkean allergiariskin 
lapsilla. Lisäksi tutkimuksen tarkoituksena oli selvittää napaveren solujen immuno-
logisia ominaisuuksia korkean allergiariskin lapsilla ja tutkia niiden ennustearvoa 
allergisten sairauksien esiintyvyyteen kahden vuoden iässä.  
 
Stimuloitujen (OKT3/anti-CD28) napaveren mononukleaaristen solujen GATA-3 
ekspressio (p = 0.03) sekä interleukiini (IL) -2 (p =0.026) ja IL-5 (p = 0.013) eritys 
olivat korkeampia kahden vuoden iässä IgE-välitteisesti herkistyneillä lapsilla, kuin 
niillä, joilla herkistymistä ei havaittu. OKT-3-stimuloitujen perifeerisen veren mo-
nonukleaaristen solujen interferoni-gamma (IFN-γ) eritys in vitro oli merkitsevästi 
vähäisempää maitoallergisilla lapsilla kuin lapsilla, joilla maitoallergiaa ei havaittu 
(p = 0.016). Lisäksi IFN-γ eritys oli alentunut lapsilla, joilla todettiin IgE-assosioitu 
maitoallergia. Lapsilla, joilla maitoallergiaan ei liittynyt IgE-assosiaatiota, perifeeri-
sen veren OKT-3-stimuloidut mononukleaariset solut erittivät merkittävästi vähem-
män IL-4-, ja IL-5-sytokiineja kuin lapsilla, joiden maitoallergiaan liittyi IgE-
välitteinen mekanismi (p = 0.002 ja p = 0.004). Lactobacillus GG (LGG) -hoito 
lisäsi perifeerisen veren mononukleaaristen solujen IFN-γ eritystä in vitro maitoal-
lergisilla lapsilla (p = 0.006) sekä lapsilla, joilla todettiin IgE-assosioitu ekseema  
  
(p = 0.017) verrattaessa lumeryhmään. Probioottinen yhdistelmävalmiste (MIX) sen 
sijaan lisäsi perifeerisen veren mononukleaaristen solujen IL-4 eritystä in vitro mai-
toallergisilla lapsilla (p = 0.028) lumeryhmään verrattaessa. LGG-hoito indusoi kor-
keampia plasman C-reaktiivisen proteiinin (CRP) (p = 0.021), ja IL-6 (p = 0.036)  
-tasoja IgE-assosiotua ekseemaa sairastavilla lapsilla lumeryhmään verrattaessa. 
Probioottinen yhdistelmävalmiste puolestaan indusoi korkeampia plasman IL-10 
tasoja ekseemaa sairastavilla lapsilla (p = 0.016): Ekseemaa sairastavilla lapsilla 
hoidon jälkeiset IL-10-tasot olivat korkeampia LGG-, ja MIX –ryhmissä kuin lume-
ryhmässä (p = 0.046 ja p = 0.039). Allergisten tautien preventiotutkimuksessa todet-
tiin korkeammat plasman CRP-, (p = 0.008), kokonais-IgA- (p = 0.016), kokonais- 
IgE- (p =0.047), ja IL-10 -tasot  (p = 0.002) probioottista yhdistelmävalmistetta 
saaneilla lapsilla verrattaessa lumevalmistetta saaneisiin. Plasman kohonnut CRP-
taso kuuden kuukauden iässä liittyi alentuneeseen ekseemariskiin kahden vuoden 
iässä, mikä oli havaittavissa myös lumevalmisteryhmässä (OR 0.4  [95% CI 0.17-
0.94], p = 0.034, koko tutkimusryhmässä). CRP-tasojen ei todettu liittyvän IgE-
herkistymiseen. 
 
Tutkimuksen johtopäätöksinä todetaan, että GATA-3 ja IL-5 -suuntautunut immuunivas-
te voi saada alkunsa jo ennen syntymää. Tämä napaveren T-solujen tasapainon suuntau-
tuminen T-auttajasolu (Th)-2 suuntaan näyttäisi liittyvän IgE-herkistymiseen varhaislap-
suudessa. Th1/Th2-tasapaino on erilainen IgE-, ja ei-IgE-assosioidussa maitoallergiassa. 
LGG-hoito nosti plasman CRP-, ja IL-6 -tasoja IgE-assosioitua ekseemaa sairastavilla 
lapsilla, mikä viittaa luontaisen immuniteetin aktivaatioon. Probioottinen yhdistelmä-
valmiste sen sijaan nosti plasman IL-10-tasoja, joten eri bakteerilajit näyttäisivät vaikut-
tavan elimistön immuunivasteeseen eri tavoin. Lisäksi probioottiset bakteerit saivat ai-
kaan erilaisen immuunivasteen eri tautimuotoja sairastavilla lapsilla viitaten siihen, että 
yksilön oma immuunijärjestelmä muokkaa probioottien vaikutuksia. Probioottinen yh-
distelmävalmiste sai aikaan matala-asteisen tulehdusreaktion korkean allergiariskin lap-
silla, mikä todettiin kohonneina plasman CRP-tasoina kuuden kuukauden iässä. Tämä 
liittyi alentuneeseen ekseemariskiin kahden vuoden iässä. Probioottiset bakteerit näyttäi-
sivät siten tuottavan hyödyllisiä elimistön immunologista tasapainoa tukevia signaaleja 
matala-asteisen tulehdusreaktion kautta. 
 
 
Avainsanat: ekseema; IgE-herkistyminen; napaveri; probiootti; T-solu 
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ABBREVIATIONS 
AD  Atopic dermatitis 
APC  Antigen presenting cell 
β-LG  Beta-lactoglobulin  
CBMCs  Cord blood mononuclear cells 
Cfu  Colony-forming units 
CM   Cow’s milk 
CMA  Cow’s milk allergy 
CRP  C-reactive protein 
CTLA  Cytotoxic T-lymphocyte-associated antigen 4 
DC  Dendritic cell 
DC-SIGN  DC-specific intercellular adhesion molecule           
  3-grabbing non-integrin 
DT  Diphtheria toxoid 
EHF  Extensively hydrolyzed whey formula 
ELISA  Enzyme-linked immunosorbent assay 
FACS  Fluorescence-activated cell sorting 
GALT  Gut-associated lymphoid tissue 
GF   Germ-free 
HDM  House dust mite  
ICAM-1  Intercellular adhesion molecule-1 
IEL  Intraepithelial lymphocyte 
IFN  Interferon 
Ig  Immunoglobulin 
IL  Interleukin 
IL-4R  Interleukin-4 receptor 
IL-12R  Interleukin-12 receptor 
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LFA-1  Lymphocyte function-associated antigen-1 
LGG  Lactobacillus rhamnosus GG 
LPS  Lipopolysaccharide  
LTA  Lipoteichoid acid 
MadCAM-1  Mucosal adressin-cell adhesion molecule  
MHC  Major histocompatibility complex 
MIX  A mixture of four bacterial strains 
MLN  Mesenteric lymph node 
NK  Natural killer cell  
OVA  Ovalbumin 
PBMCs  Peripheral blood mononuclear cells 
PHA  Phytohaemaglutinin 
PRR  Pattern recognition receptor 
RAST  Radioallergosorbent test 
RT-PCR  Reverse transcriptase-polymerase chain reaction 
SEB  Staphylococcus aureus enterotoxin B 
sIgA  Secretory immunoglobulin class A 
SPF  Specific pathogen-free 
SPT  Skin prick test 
SCORAD  Severity Scoring of Atopic Dermatitis 
T-bet  Th1-specific T-box transcription factor 
TCR  T-cell receptor 
TGF  Transforming growth factor 
Th  T-helper 
TLR  Toll-like receptor 
TNF  Tumor necrosis factor 
TT  Tetanus toxoid 
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1 INTRODUCTION 
The prevalence of allergic diseases continues to increase in the developed world and 
constitutes a common health problem among children (Asher et al. 2006; von 
Mutius 1998). Early infancy is a critical period for the development of 
immunological memory, while the T helper (Th) balance converts from the        
Th2-skewed immunity to Th1 cell-type responses under the influence of genetic and 
environmental factors (Wegmann et al. 1993). Studies suggest that postnatal 
maturation of the immune system in atopic individuals is attenuated, and atopic 
infants show an imbalance in Th1/Th2 immune responses (Holt and Jones 2000; 
Prescott and Holt 1998; Prescott et al. 1999). A number of regulatory T-cells appear 
to be involved in regulating Th responses, and defects in regulatory T-cell responses 
have been linked to allergic diseases (Akbari et al. 2003; Stock et al. 2006; Taylor et 
al. 2006b; Wing and Sakaguchi 2006). New strategies to reduce the risk for allergies 
are clearly needed, and as the period of immunological maturation, pregnancy or 
early infancy may be critical for preventing the onset of allergic disease. 
 
The reduced microbial contact or changes in microbial balance in early infancy may 
have altered the prevalence of allergies. According to the “hygiene hypothesis”, 
infections and unhygienic conditions may confer protection against the development 
of allergic diseases (Strachan 1989). This hypothesis originated from  
epidemiological findings of an inverse correlation between family size and allergic 
rhinitis. The hypothesis has, ever since, undergone numerous modifications, and 
limited exposure to bacterial and viral pathogens during childhood has been 
proposed to result in insufficient stimulation of Th1 cells, the expansion of Th2 
cells, and predisposition to allergic diseases (Martinez and Holt 1999; Matricardi et 
al. 1997, 2000). Studies on autoimmune diseases and helminth infections have, 
however, shown that this increase cannot merely be due to the  Th1-Th2 imbalance 
(Bach 2002; Stene and Nafstad 2001). Interestingly, populations with a high 
incidence of helminth infections favouring a Th2-skewed immune response are 
protected from allergic diseases (Yazdanbakhsh et al. 2001). A modified version of 
the hygiene hypothesis, the “germless theory” explains that all types of microbial 
stimulation (both Th1- and Th2-polarizing) induce regulatory cells which produce 
immunosuppressive cytokines (IL-10 and TGF-β) and control immune 
responsiveness (Wills-Karp et al. 2001).  
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Interest in the role of the intestinal flora in shaping mucosal immune responses has 
increased in recent years. The intestinal microbes may play a crucial role in the 
development of oral tolerance. Studies in germ-free mice suggest that exposure to 
intestinal bacterial strains during infancy stimulates the maturation of the intestinal 
immune system and is required for the development of oral tolerance (Maeda et al. 
2001; Sudo et al. 1997).  
 
Several studies suggest that the quality of the indigenous intestinal flora may affect 
the development of allergic diseases, which often results in failure in oral tolerance. 
A reduced ratio of bifidobacteria to clostridia has appeared in infants developing 
atopy (Kalliomäki et al. 2001a), and allergic patients have been shown to be more 
often colonized with clostridia and staphylococci, and have fewer enterococci and 
bifidobacteria than do non-allergic patients (Björksten et al. 2001; Kalliomäki et al. 
2001a; Watanabe et al. 2003). Gut microbiota composition can precede the 
manifestation of atopic outcomes, while early colonisation with Escherichia coli has 
been associated with higher risk for developing eczema, and Clostridium difficile 
with eczema, recurrent wheeze, and allergic sensitization in infancy (Penders et al. 
2007). Limited exposure to microbial antigens during early infancy, changes in diet 
and conservation and preparation (Metchnikoff 1910) of foods may have altered the 
composition of the gut flora. These changes may be counter-balanced by probiotic 
bacteria, which are proposed to provide beneficial immunoregulatory signals 
promoting oral tolerance achievement and alleviating symptoms of allergic diseases. 
Despite their positive clinical effects on the prevention and treatment of atopic 
diseases (Majamaa and Isolauri 1997; Isolauri et al. 2000; Kalliomäki et al. 2001b, 
2003; Rosenfeldt et al. 2003; Viljanen et al. 2005b; Abrahamsson et al. 2007) the 
immunological effects of probiotic bacteria are, however, largely unknown. 
 
The purpose of the present study was to evaluate the effects of probiotic bacteria on 
the immunologic and inflammatory response in infants with allergic diseases, as 
well as probiotics' role as a preventive among allergy-prone infants. Furthermore, 
the immunological features of the CBMCs were characterised in infants at high 
genetic risk for allergic diseases.  
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2 REVIEW OF THE LITERATURE 
2.1 Components of the immune system 
 
2.1.1 Innate immune system 
 
The innate immune system provides an immediate response against environmental 
pathogens. A variety of non-specific mechanisms, such as permeability control with 
epithelial cells and tight junctions, secretion of mucus, digestive enzymes, low pH, 
and peristalsis, operate to establish the host barrier against intruders. The innate 
response includes neutrophils, monocytes, macrophages, natural killer cells, 
complement, and acute phase proteins. The activation of the innate immune 
response is not pathogen-specific, but is dependent in large part on ligand-binding 
receptors, pattern recognition receptors (PRRs) (Kaisho and Akira 2006). PRRs can 
be functionally classified into signalling and non-signalling (Kaisho and Akira 
2006). The best-characterised signalling PRRs are Toll-like receptors (TLRs), which 
recognise a diverse family of ligands produced by bacteria, viruses, and fungi. TLRs 
are mainly expressed on antigen-presenting cells (APCs) such as macrophages and 
dendritic cells (DCs), where they alert the immune system to the presence of a 
pathogen, but also help initiate adaptive immune responses through the activation 
and maturation of DCs (Medzhitov 2001; Takeda et al. 2003; Kaisho and Akira 
2006). TLRs detect microbial products such as lipopolysaccharide (LPS) and 
lipoteichoid acid (LTA), recognized by TLR4 and TLR2, respectively (Takeda et al. 
2003). Various TLRs are distributed differentially between inflammatory cells, and 
recognise different pathogens. Signalling via TLRs can induce the production of 
pro-inflammatory mediators such as cytokines and chemokines (e.g., IFN-γ and    
IL-12). TLRs functioning as sensors is critical for the initiation of inflammatory and 
immune defence responses, but the bacterial ligands recognized by TLRs are not 
unique to pathogens. They are shared with commensal bacteria as well, and this 
interaction of TLRs with commensal flora plays a crucial role in the maintenance of 
intestinal epithelial homeostasis (Rakoff-Nahoum et al. 2004). TLR ligand exposure 
may provide an important link between microbes, normal immune development, and 
the atopic phenotype (Braun-Fahrlander et al. 2002; Abreu et al. 2005).  
 
Nonsignalling PRRs include soluble factors such as acute phase proteins, and 
transmembrane proteins such as scavenger receptors. C-reactive protein (CRP) is an 
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acute-phase protein produced exclusively in the liver and released into the 
circulation by activated hepatocytes. It can bind to the invading micro-organisms, 
leading to phagocytosis or to recognition of the complement system (Kaisho and 
Akira 2006). In clinical practise, CRP has been widely used as an indicator of 
inflammatory processes such as bacterial infections. In such conditions, CRP levels 
rise in serum or plasma within 24 to 48 hours after acute tissue damage, peaking at 
the acute stage and decreasing with resolution of inflammation (Macy et al. 1997; 
Morley and Kushner 1982). Minor increases in CRP have turned out to reflect 
subclinical inflammation such as atherosclerosis (Cesari et al. 2003; Ridker et al. 
1998; Taubes 2002), but its role in allergic disorders is unclear. IL-6 induces CRP 
gene expression and stimulates secretion of CRP in hepatocytes (Li and Goldman 
1996). In allergic reactions, increased serum CRP levels have been shown to 
correlate positively with plasma IL-6 levels (Fujii et al. 2001; Lin et al. 2001). 
 
2.1.2 Adaptive immune system 
 
The adaptive immune response is mediated by antigen-specific T- and                    
B-lymphocytes. Adaptive immune responses are generated in secondary lymphoid 
tissues (lymph nodes, mucosa-associated lymphoid tissue, and spleen). T-cells carry 
T-cell receptors (TCR) on their surfaces. These receptors in CD4+ T-cells recognise 
short peptides of exogenous antigens presented in class II major histocompatibility 
complex (MHC) molecules, which are expressed on APCs, such as DCs, 
macrophages and B-cells. CD8+ T-cells recognise peptides of endogenous antigens 
on class I MHC molecules, which are expressed on all somatic cells in the body.    
B-lymphocytes recognise antigens with immunoglobulins as being antigen 
receptors. An efficient adaptive immune response with antigen-specific T- and       
B-cell populations with clonally distributed receptors take several days or weeks to 
develop. The pattern of cytokines that are present during the clonal expansion 
mainly drive the polarization of T-helper (Th)-cells into a Th1 or Th2 type.        
Th1-cells are effective against intracellular and Th2 extracellular pathogens, and 
Th2 associated also with atopic diseases (Mosmann et al. 1986; Del Prete et al. 
1991;  Abbas et al. 1996). Recently, the Th1/Th2 division has been revised, because 
another functional Th subset has been found, called Th17. Activation of the Th17 
pathway plays a role in autoimmune diseases and is associated with susceptibility to 
Crohns disease and ulcerative colitis (Steinman 2007). The Th17 pathway is now 
implicated in the cause and continuation of tissue damage in various models of 
immune-mediated tissue injury, but its role in allergic diseases remains to be 
elucidated (Steinman 2007). In addition, several types of regulatory T-cells such as 
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Th3 cells, T regulatory type 1 (Tr1) cells, CD4+CD25+ cells, CD8+ -suppressor T-
cells, and γδ T-cells modulate adaptive immune responses by inhibiting harmful 
immunopathological responses directed against self or foreign antigens (Maloy and 
Powrie 2001). In contrast to innate immunity, the adaptive response mediated by 
antigen-specific T- and B-cells has memory, leading to more efficient and rapid 
responses to recall antigens. 
 
Adaptive immune responses can be divided into functionally polarized responses by 
the CD4+ Th-cell subsets, defined on the basis of cytokine production patterns 
(Mosmann et al. 1986; Del Prete et al. 1991; Abbas et al. 1996). Th1 and Th2 
subsets are believed to develop from the same T-cell precursor, whose 
differentiation is influenced by microenvironmental stimuli. The T-bet, a            
Th1-specific T-box transcription factor, initiates Th1 lineage development and 
controls the expression of the hallmark Th1 cytokine, IFN-γ, which is secreted upon 
activation of the IL-12 receptor (IL-12R) (Szabo et al. 1997, 2000). Functional 
differences between Th1 and Th2 subsets are explained by their cytokine secretion 
pattern. Interleukin (IL)-12, which is produced by activated macrophages and 
dendritic cells, is the principal Th-1-inducing cytokine (Abbas et al. 1996). Th1 cells 
produce interferon-gamma (IFN-γ), IL-2, and tumour necrosis factor-beta  (TNF-β), 
with few or no Th2-type cytokines (Mosmann et al. 1986; Del Prete et al. 1991).   
IL-4 and IL-13 antagonize IFN-gamma, which is a Th1-type cytokine having 
macrophage-activating properties (Abbas et al. 1996; Romagnani 2000).Th1 cells 
play a central role in immune defence against intracellular pathogens.  
 
Expression of the transcription factor GATA-3 is strongly associated with Th2 
differentiation of the naive CD4 cells. In T-cells, GATA-3 activates and stabilises 
the expression of IL-4, IL-5, and IL-13, and represses Th1-type-specific genes like 
IFN- γ (Zhang et al. 1997, 1998; Zheng and Flavell 1997; Lavenu-Bombled et al. 
2002). Th2 cells provide aid for humoral responses such as antibody production, 
especially of the IgE class (Coffman and Carty 1986; Del Prete et al. 1988).         
Th2-type cytokines are involved in defence against helminth infections 
(Yazdanbakhsh et al. 2001, 2002), and a Th2-skewed immune response has been 
associated also with atopic diseases such as atopic eczema (Reinhold et al. 1991; 
Leung and Bieber 2003), asthma (Robinson et al. 1992; Busse and Lemanske 2001), 
and food allergy (Andre et al. 1996; Beyer et al. 2002). Th2 cells secrete IL-4, IL-5, 
IL-9, IL-13, IL-6, and IL-10. The principal Th2 type cytokines are IL-4 and IL-5 
that help B-cells to proliferate and differentiate. IL-4 is associated with          
humoral-type immune responses, inducing B-cell switching to IgE production, and 
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being a key initiator of IgE-dependent, mast-cell-mediated reactions (Galli 1993). 
IL-5 activates eosinophils (Abbas et al. 1996). IL-9 enhances mast cell 
differentiation, IL-13 increases IgE synthesis, and mucus production, and induces 
airway hyper-reactivity, and IL-10 has anti-inflammatory action.   
 
B-cells recognise antigens with immunoglobulins as being antigen receptors. Naïve 
B-cells express immunoglobulin (Ig) M (IgM) and IgD antibodies on their cell 
surfaces, mature B-cells switch to the IgG, IgA, or IgE surface receptors. B-cell 
responses are modulated by activated T-cells. They induce immunoglobulin class 
switching in    B-cells by expressing CD40 ligands on their cell surfaces and by 
binding to the receptors, CD40 on B-cell surfaces, and then switching is activated 
(Pene et al. 1988; Mowat 2003). 
 
2.2 Atopy and allergic diseases 
 
2.2.1 Definitions  
 
The nomenclature and definition of atopy and allergic diseases have evolved over 
time, and their terminology has been confusing. A standardised nomenclature of 
allergy was proposed by the European Academy of Allergy and Immunology in 
2001 (Johansson et al. 2001) and was revised in 2004 (Johansson et al. 2004). 
According to this nomenclature, “atopy” is to be defined as a “personal or familial 
tendency to produce IgE antibodies in response to low doses of allergens, usually 
proteins, and to develop typical symptoms such as asthma, rhinoconjunctivitis, or 
eczema/dermatitis.” The term “atopy” is reserved for describing clinical traits and a 
genetic predisposition to become IgE-sensitized to environmental allergens, and can 
not be used if IgE-sensitization has not been documented by a positive skin prick 
test or by IgE antibodies in serum.  According to the nomenclature,  “allergy” is to 
be defined as a “hypersensitivity reaction initiated by immunologic mechanisms”; 
based on the immunological mechanisms involved, allergy is classified into        
IgE-mediated allergy or non-IgE-mediated allergy (Johansson et al. 2001). In cow’s 
milk allergy (CMA), the immunological reaction is toward proteins of cow’s milk 
(CM). The symptoms of food allergy may manifest in different organs, including the 
skin (urticaria, eczema) and the gastrointestinal tract (vomiting, diarrhoea, 
constipation, abdominal pain, gastroesophageal reflux). Asthma is a lung disease 
characterised by bronchial hyperresponsiveness, inflammation, a variable degree of 
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airway obstruction (Busse and Lemanske 2001). According to the standardised 
nomenclature, asthma resulting from immunological reactions should be called 
allergic asthma; nasal hypersensitivity symptoms such as itching, sneezing, 
increased secretion, and blockage, when immunologically mediated, should be 
called allergic rhinitis. Allergic rhinitis accompanied by itchy and watery eyes 
should be called allergic rhinoconjunctivitis (Johansson et al. 2001, 2004). Atopic 
eczema/atopic dermatitis is defined as a chronic, relapsing, itching, inflammatory 
skin disease with a typical distribution and morphology (Hanifin and Rajka 1980; 
Bohme et al. 2000), but according to the standardised nomenclature of allergy 
proposed by the European Academy of Allergy and Immunology, only an           
IgE-antibody-associated reaction to an antigen would allow the use of the term 
atopic eczema, and without the IgE-association (no documentation of a positive skin 
prick test reactivity or IgE antibodies in serum), the correct definition is eczema 
(Johansson et al. 2004). 
 
2.2.2 Epidemiology 
 
The prevalence of atopy and allergic diseases has increased in most industrialised 
countries worldwide during the last 20 years (von Mutius 1998). An international 
study of asthma and allergic diseases in children aged 9 to 11 years reported 
considerable variation in the prevalence of asthma and allergies between countries. 
The lowest prevalence rate of asthma was reported in Albania (2%), while the 
highest prevalence rate (33%) was found in the United Kingdom (Weiland et al. 
2004). The prevalence of atopic eczema was reported to be less than 2% in Iran to 
over 16% in Sweden and Japan among 6- to 7-year-old children, and less than 1% in 
Albania to over 17% in Nigeria among 13- to 14-year-olds (Williams et al. 1999). 
The prevalence of childhood asthma, rhinitis, and eczema among 11- to 13-year-old 
children varied considerably in Scandinavia and eastern Europe. The prevalence of 
wheezing was high (11.2-19.8%) in Finland and Sweden, lower in Estonia, Latvia, 
and Poland (7.6-8.4%), and lowest in Albania, Romania, Russia, Georgia, and 
Uzbekistan (2.6-5.9%). The 12-month prevalence of flexural dermatitis and itching 
eyes varied in a similar manner between the three regions (Björksten et al. 1998). 
The highest prevalence of rhinitis was recorded between April to July in 
Scandinavia and during the winter in the other countries (Björksten et al. 1998). 
Recently, a mean 7 years after its Phase One, the International Study of Asthma and 
Allergies in Childhood (ISAAC), was repeated, to examine the changes in the 
prevalence of symptoms of these disorders. Most centres showed a change in 
prevalence of 1 or more standard error of the mean for at least one disorder, with 
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increases being twice as common as decreases. An exception was asthma symptoms 
in the 13- to 14-year-age-group, in which decreases were more common in         
high-prevalence countries (Asher et al. 2006). Frequencies of food allergies have 
been difficult to determine, when a range of symptoms are reported as allergic. In 
Finland, 2% of infants have been reported to suffer challenge-test-proven CMA at 
age one year (Saarinen et al. 1999).  IgE-mediated CMA may persist to school age 
and is a risk factor for other atopic diseases, whereas non-IgE-mediated CMA is a 
benign infantile condition (Saarinen et al. 2005).  
 
2.2.3  Immunological basis of atopy and allergic diseases  
 
In IgE-mediated allergic reactions, the IgE molecule plays a central role in the 
pathogenesis of immediate hypersensitivity reactions (10-20 minutes) by virtue of its 
capacity to bind specifically to high-affinity IgE receptors on mast cells and to 
mediate the release of various mast cell-derived mediators (e.g. histamine, tryptase, 
leukotriene, and prostaglandin) and proinflammatory cytokines on exposure to 
allergen. Immediate allergic responses are followed by a late-phase response           
(4-8 hours) dominated by eosinophils and T-lymphocytes (Kay 2001; Platts-Mills 
2001). The majority of T-cells in allergic responses are memory T-cells secreting 
helper type 2 (Th2)-type cytokines: IL-4, IL-5, and IL-13. IL-4 and IL-13 regulate 
IgE synthesis, and IL-5 promotes eosinophil development, thus contributing to 
allergic inflammatory responses. The immunological definition for “atopic allergy” 
suggests that atopy is a “T-helper (Th)2 -driven hypersensitivity to innocuous 
antigens (allergens) of complex genetic and environmental origins” (Romagnani 
1994, 1998). Positive skin prick test reactivity and specific IgE antibody production 
against antigens with allergic symptoms serve in diagnosing IgE-mediated allergic 
disease (Kay 2001). The non-IgE-mediated allergic reactions are often delayed 
hypersensitivity reactions starting over 2 hours after antigen contact (from 2 hours to 
several days) (Kay 2001; Sabra et al. 2003; Sampson 2004). The intestinal 
symptoms are commonly observed in these delayed reactions. The immunological 
mechanism behind the non-IgE-mediated allergy is, however, poorly characterised, 
and there exist no specific markers as diagnostic tools for non-IgE-mediated allergy. 
Imbalance of the Th1/Th2 cells has been associated with allergic diseases. In      
IgE-mediated allergic reactions, the development and activation of allergen–specific 
T-helper type 2 (Th2) cells leads to tissue damage, and in non-IgE-mediated allergic 
reactions, the polarization and activation of allergen–specific T-helper type 1 (Th1) 
cells leads to immunologic injury (Kay 2001; Sabra et al. 2003; Sampson 2004).   
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The interpretation of the Th1/Th2 paradigm in understanding of atopy and allergic 
diseases is prone to ambiguity. New paradigms encompassing a more diverse set of 
cell types have been developed to explain the immunological events that regulate 
these disorders. New observations have raised the suggestion that an imbalance 
between immunoregulatory and Th2 effector mechanisms can modulate allergy in a 
critical fashion (Wills-Karp et al. 2001; Yazdanbakhsh et al. 2001; Umetsu et al. 
2002; Akbari et al. 2003; Akdis et al. 2004;). Sakaguchi and colleagues made the 
observation that depletion of CD25+ cells induces multiorgan autoimmunity 
(Sakaguchi et al. 1995; Asano et al. 1996), which began the modern view of 
regulatory T-cells. Several types of regulatory T-cells occur: Th3 cells, T-regulatory 
type 1 (Tr1) cells, CD4+CD25+ cells, CD8+ -suppressor T-cells and γδ T-cells 
(Sicherer and Sampson 2006).  
 
Th3 cells originate from the mucosa, are activated by mucosal antigens, and secrete 
transforming growth-factor beta (TGF-β) and variable amounts of IL-4 and IL-10 
(Chen et al. 1994; Weiner 2001). Increased IL-10 and TGF-β levels have been 
associated with induction of oral tolerance (Zemann et al. 2003). Tr1 cells produce 
high levels of IL-10, which down-regulates allergen-specific Th1 and Th2 responses 
(Akdis et al. 2004). CD4-positive cells expressing high levels of CD25 
(CD4+CD25+ cells) are produced by the normal thymus as a functionally mature 
population, and constitute 5 to 10% of peripheral CD4+ T-cells in humans. These 
cells are associated with the transcription factor FoxP3 (Fontenot et al. 2003). Jaffar 
and colleagues showed in a murine model that CD4+CD25+ T-regulatory cells 
suppress antigen-induced airway eosinophilic inflammation via their influence on 
the development of the Th2 phenotype (Jaffar et al. 2004). In a clinical study, 
children who outgrew their allergy had higher frequencies of circulating 
CD4+CD25+ T-cells and lower (in vitro) proliferative responses to bovine              
β-lactoglobulin in PBMCs than did children who maintained an allergic state 
(Karlsson et al. 2004). Ling and colleagues (2004) demonstrated that CD4+CD25+ 
regulatory cells from atopic individuals have a decreased capacity to suppress 
allergen-driven proliferation and Th2 response in vitro, when compared with that of 
non-atopic individuals, suggesting that inadequacy of T-regulatory-cell function 
may be related to a deficiency in the suppressive activity of CD4+CD25+ T-cells 
rather than their insufficient number. The suppressive mechanism of CD4+CD25+ 
cells is suggested to function via the negative regulator of T-cell activation, 
cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), and secretion of the 
immune-suppressive cytokine TGF-β (Read et al. 2000; Annunziato et al. 2002).  
IL-10 and TGF-β suppress IgE production, induce the non-inflammatory 
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immunoglobulin isotypes IgG4 and IgA, and directly suppress allergic inflammation 
by suppressing mast cells, basophils, and eosinophils (Taylor et al. 2006b). 
 
Studies suggest that some of the CD4+CD25+ cells do not originate from the 
thymus, and existing evidence supports the idea that CD4+CD25+ cells are a 
heterogenous population that can be peripherally induced by foreign antigens 
(Maloy and Powrie 2001). It has also been proposed that in addition to CD4+ T 
cells, CD8+ TReg cells play a role in oral tolerance (Weiner 1997). Based on the 
literature, Th-2 skewed immune responsiveness is well established in atopy; 
however, the regulatory T-cells seem to play an important role in the events leading 
to polarization, and this needs further elucidation.  
 
2.2.4 Fetal immune system and transplacental priming 
 
Normal fetal development occurs in an environment biased towards a T-helper-type 
(Th)2 immunity, which is considered to be fundamental to a successful pregnancy 
(Lin et al. 1993; Wegmann et al. 1993). The placenta produces high levels of 
mediators which are Th2-trophic or Th1-suppressive or both, including 
prostaglandin E2 (Hilkens et al. 1995), progesterone (Piccinni et al. 1995), IL-4, and 
IL-10 (Roth et al. 1996). By contrast, Th1-type cytokines are associated with 
cytotoxic effects, which are harmful during pregnancy (Piccinni and Romagnani 
1996). Thus, exogenous antigens that leak across the placenta are likely to be 
presented to the fetal immune system within a milieu of positive selection for     
Th2-type immunity. Observations in lymphocyte stimulation studies suggest that the 
priming of the immune system to allergens already may have occurred before birth 
(Jones et al. 1996; Szepfalusi et al. 1997), followed by several studies demonstrating 
cord blood mononuclear cells (CBMCs) to be able to produce cytokines in response 
to specific allergens, indicating prenatal transplacental sensitization (Warner et al. 
1994; Kondo et al. 1998; Prescott et al. 1998a;  Lange et al. 2003). 
 
Neonatal allergen-specific proliferative responsiveness is associated with genetic 
risk for atopic diseases (Devereux et al. 2002). Interestingly, studies have also 
shown a reduced number of IFN-γ-producing cells (Nilsson et al. 2004) and reduced 
IFN-γ secretion of CBMCs, and a greater Th2-biased allergen responsiveness of 
CBMCs in infants with allergic diseases or sensitization during their first years of 
life (Tang et al. 1994; Warner et al. 1994; Liao et al. 1996; Kondo et al. 1998; 
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Neaville et al. 2003). Prescott and colleagues showed neonatally reduced levels of 
both Th1 and Th2 type cytokines, including IFN-γ, IL-4, IL-6, IL-10, and IL-13 in 
infants developing atopic disease as compared to levels in healthy infants (Prescott 
and Holt 1998; Prescott et al. 1999). Studies of CBMC IL-13 secretion have given 
conflicting results: Enhanced IL-13 levels at birth have been associated with the 
subsequent development of atopic symptoms (Spinozzi et al. 2001; Ohshima et al. 
2002; Lange et al. 2003), but in contrast, Williams et al. (2000) reported lower levels 
of IL-13 in neonates who subsequently developed atopic symptoms until age 3. An 
elevated frequency of IL-4-producing CBMCs and IL-4/IFN-γ ratio in response to 
PHA-stimulation as well as lower numbers of IL-12-producing cells in CBMCs have 
been detectable in newborns at high risk for atopy (Gabrielsson et al. 2001). In other 
studies, a pronounced production of IL-4 and IL-5 in CBMC was associated with the 
subsequent development of atopy (Piccinni et al. 1996; Sharp et al. 2003). 
 
2.2.5 Postnatal development of immunity and atopy  
  
At birth, the infant`s immune system is immature. Neonatal cytokine levels are low, 
T-cell cytotoxity and B-cell functions are limited, and granulocyte and complement 
functions of the innate immune system are immature  (Holt and Jones 2000). The 
levels of IgA, IgM, and IgE antibodies in serum are low in infants not exposed to 
infectious agents, and the neonatal IgG antibody is mainly of maternal origin (Holt 
and Jones 2000). The IgG concentration starts to decrease soon after birth, leading to 
a physiological hypogammaglobulinemia by the age of  3 to 4 months. Adult IgG 
antibody levels are reached by the age of 4 to 6 years (Kapur et al. 2002). The 
circulating IgM level at birth is only 5 to 20% of the adult level (Hayward 1998, 
Kapur et al. 2002), and adult levels are reached by the age of 1 to 2 years (Kapur et 
al. 2002).  The adult level of IgA in serum is reached at puberty (MacDonald et al. 
1996; Kapur et al. 2002), but in the intestine, in lamina propria, adult levels are 
reached by the age of 2 (Savilahti 1972). Retarded postnatal IgA development has 
been associated with atopic outcome (Taylor et al. 1973; Orgel et al. 1975). The 
defining hallmark of atopic disease is the production of specific IgE to allergens, 
leading to allergic inflammation and disease. High IgE levels in cord blood are 
highly specific for atopic diseases, but their sensitivity in predicting atopy has been 
low (Arshad et al. 1993; Kobayashi et al. 1994; Bergmann et al. 1997; Edenharter et 
al. 1998). 
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Neonatal immune responses are dominated by a Th2-biased cytokine pattern in 
virtually all infants (Prescott et al. 1998a). Atopic infants develop persistent       
Th2-biased immune responses to environmental antigens along with their 
insufficient Th1-type immunity (Prescott and Holt 1998; Prescott et al. 1999; Holt 
and Jones 2000). Non-atopic infants show a gradual fall in Th2 responses to 
allergens, and the balance deviates toward Th1-biased immune reactions on average 
during the first year of life (Holt et al. 1997; Prescott et al. 1999; van der Velden et 
al. 2001). In atopic individuals, postnatal maturation of the immune system is 
attenuated, and an adult-like cytokine pattern is achieved by age 6  (Macaubas et al. 
2000). Delayed Th1 maturation and Th-2-skewed immunity against allergens in 
atopic children has been argued to associate with poorer IgG responses to vaccines 
(Prescott et al. 1998b; Arkwright et al. 2000; Holt et al. 2000). 
 
In addition to the mutual antagonism between Th1 and Th2 responses, the postnatal 
development and regulation of immunity is mediated by the activation of other       
T-cell types: T-regulatory cells. Atopic individuals have defects in regulatory T-cell 
responses (Lee et al. 2000; Akbari et al. 2003; Perez-Machado et al. 2003; Akdis et 
al. 2004; Stock et al. 2006; Taylor et al. 2006b; Wing and Sakaguchi 2006).  
 
2.2.6 Hygiene hypothesis  
 
The idea that infections and unhygienic conditions may confer protection against the 
development of allergic diseases was first introduced by Strachan (1989). The 
“hygiene hypothesis” originated from epidemiological findings with an inverse 
correlation between family size and allergic rhinitis. This hypothesis, also called the 
“germless theory” (Wills-Karp et al. 2001), has ever since undergone numerous 
modifications. It has been postulated that limited exposure to bacterial and viral 
pathogens during early childhood results in insufficient stimulation of Th1 cells,  
expansion of Th2 cells, and predisposition toward allergic diseases (Martinez and 
Holt 1999; Matricardi et al. 1997, 2000). Studies of autoimmune diseases and 
helminth infections have, however, shown that this increase in allergic diseases 
cannot merely be accounted for by the Th1-Th2 imbalance. The prevalence of     
Th1-related diseases has increased during the last decades, ones such as diabetes 
mellitus and Crohns disease (Bach 2002), with an association between the 
occurrence of asthma and diabetes (Stene and Nafstad 2001). Populations with a 
high incidence of helminth infections favouring a Th2-skewed immune response are 
protected from allergic diseases (Yazdanbakhsh et al. 2001). Wills-Karp and 
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colleagues (2001) have proposed that all types of microbial stimulation (both     
Th1- and Th2-polarizing) induce regulatory cells which produce immunosuppressive 
cytokines (IL-10 and TGF-β) and control immune responsiveness. Recent research 
on the molecular mechanisms of the hygiene hypothesis highlights the role of    
Toll-like receptors in innate responses to microbes. These receptors recognise 
ligands produced by fungi, viruses, and bacteria, and are believed to modulate 
allergic inflammation and the development of host immune responses (Horner 2006; 
Vercelli 2006).                                                                                  
 
2.3 Gut immune system 
 
2.3.1 Functional parts of the gut immune system 
 
The immune system in the gastrointestinal tract, designated to gut-associated 
lymphoid tissue (GALT) is the largest compartment of the human immune system. It 
consists of Peyer’s patches found in the submucosa mainly in the small intestine and 
appendix, solitary lymph follicles present in the colon and ileum, mesenteric lymph 
nodes (MLNs), and lymphocytes scattered throughout the lamina propria (lamina 
propria lymphocytes) and intestinal epithelium (intraepithelial lymphocytes, IELs). 
 
Peyer’s patches consist of large B-cell follicles and intervening T-cell areas, which 
are separated from the intestinal lumen by a single layer of columnar epithelial cells. 
Overlying Peyer’s patches and between gut epithelial cells (enterocytes) lie 
microfold cells (M-cells), which are specialized in antigen uptake from the intestinal 
lumen and its transport across the mucosal surface. Antigens can also be taken up 
and processed by DCs. After antigen contact, these cells move to the T-cell areas or     
B-cell follicles in Peyer’s patches, where antigens are processed and presented to   
T-cells, leading to the activation of T-cells, and subsequently of B-cells (Fig 1).  
 
Activated T-cells migrate from T-cell areas (subepithelial dome and interfollicular 
region) via afferent lymphatics to the mesenteric lymph nodes, differentiate, and 
migrate to the thoracic duct, and eventually gain access to the systemic circulation. 
From the circulation, the activated lymphocytes migrate with the help of adhesion 
molecules to the lamina propria and intraepithelial compartment of the intestine, 
where they mediate adaptive immune defence (Fig 1). 
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Figure 1.  Antigen uptake and recognition by CD4+ cells in the gut-associated 
lymphoid tissue (GALT). Antigen may be taken up via microfold (M) cells or epithelial 
cells.  Local antigen-precenting cells (APCs) process and present antigen to   T-cells in 
Peyer’s patches, which leads to the activation of T-cells, and subsequently of B-cells.  
The activated cells migrate via draining lymphatics to mesenteric lymph nodes (MLNs), 
the thoracic duct, and finally to the systemic circulation. A similar process occurs if 
antigen enters through the epithelium covering the villus lamina propria, but there is a 
further possibility that MHC class II+ enterocytes may act as local APCs. From the 
circulation, the activated lymphocytes migrate with the help of adhesion molecules to the 
lamina propria and intraepithelial compartment of the intestine, where they mediate 
adaptive immune defence (modified from Mowat 2003). 
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Activated T-cells secrete cytokines which modulate B-cell responses, IL-10 and 
TGF-β favour IgA class switching, while IL-4 induces IgE and IgG secretion (Pene 
et al. 1988; Mowat 2003). Following class-switching, B-cells migrate from Peyer’s 
patches into regional lymph nodes, the circulation, and finally into the lamina 
propria, where activated B-cells proliferate and differentiate into plasma cells and 
some of them further into memory cells. Mucosal B-cell function in the intestine is 
characterised by the production of secretory IgA (sIgA), a dimer of two IgA 
molecules covalently linked together through a J-chain molecule between the alpha 
heavy chains. This complex is translocated through intestinal epithelial cells to the 
intestinal lumen (Brandtzaeg and Prydz 1984). The sIgA inhibits the colonisation of 
pathogens and penetration of luminal antigens and is proposed to make complexes 
with antigens, thus aiding removal of foreign particles from the body (Mayer 2000; 
Macpherson et al. 2001). 
 
The lamina propria contains a large number of DCs, which pick up dietary antigens 
and present them to T-cells. IL-10-producing DCs are suggested to play an 
important role in induction of oral tolerance (Mowat 2003). In the lamina propria, 
approximately two-thirds of T lymphocytes are CD4+ T-cells, and one-third CD8+ 
T-cells. CD4+ T-cells play a central role in the local immune defence of the gut by 
producing high levels of cytokines upon stimulation, particularly IFN-γ, but also   
IL-4 and IL-10 (Braunstein et al. 1997; Carol et al. 1998; Hurst et al. 1999). 
However, their proliferation response after mitogen stimulation or specific antigen 
stimulation is poor, probably relating to their state of maturation and activation 
(Braunstein et al. 1997; Hurst et al. 1999; Mowat 2003). T-cells with previous 
contact with antigen, memory T-cells, are a major constituent of the lamina propria 
and epithelium. Some of the activated lamina propria CD4+ cells are true effector 
cells, helping B-cells to produce IgA (Mowat 2003). A fraction of lamina propria 
CD4+ T-cells act as regulatory T-cells and play an important role in development 
and maintenance of tolerance to dietary antigens, and in the normal microbial 
balance of the gut (Mowat 2003; Sakaguchi 2000).  
 
The mucosal surface of the intestine is covered with a single layer of epithelial cells, 
which constitutes a physical barrier to luminal particles and regulates nutrient uptake 
and permeability. Epithelial cells express MHC class II molecules on their surfaces, 
and are able to take up antigens by endocytosis and present antigens to primed       
T-cells (Mayer 1998). Epithelial cells play an important role in the uptake and 
transport of secretory IgA (sIgA) into the gut lumen via a membrane-bound receptor 
(Brandtzaeg and Prydz 1984), and are able to produce pro-inflammatory cytokines 
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in response to pathogens. The signals responsible for pro-inflammatory activation 
can be modified or inhibited by interactions between epithelial cells and commensal 
bacteria (Haller et al. 2000; Neish et al. 2000). The epithelial barrier is therefore able 
to interact with commensal bacteria and send crucial signals to the underlying 
immune cells. The intestinal epithelium also contains intraepithelial IELs, which are 
separated from the intestinal lumen only by the tight junctions of the epithelial cells. 
The majority of IELs are T-cells, 80 to 90% being cytotoxic CD8+ cells and only 
very few B-cells or natural killer cells. Most IELs express TCRα/β and CD45RO, 
suggesting that they are antigen-primed memory cells (Brandtzaeg et al. 1989).  
 
The selective recruitment of lymphocytes, a process which directs cells back to the 
location where they first encountered their antigen and potentially meet their 
specific antigen again, makes the immune response very effective.  Molecules that 
play an important role in this homing process, the adhesion molecules, can be 
divided into selectins, integrins, and immunoglobulin (Ig) superfamily adhesion 
molecules. Numerous adhesion molecules have been implicated in the selective 
recruitment of lymphocytes in the gut, with the α4β7-MadCAM-1 integrin-addressin 
pair suggested to be the most important (Salmi and Jalkanen 1999). Endothelial cells 
in high endothelial venules express the mucosal adressin-cell adhesion molecule 
(MadCAM-1), which is normally expressed exclusively in the gastrointestinal 
mucosa. Its ligand, α4β7-integrin, in lymphocytes specifically facilitates binding to 
the epithelium and migration of lymphocytes into the mucosal tissue of the gut 
(Eigenmann 2002). The CCL25 receptor, CCR9, also plays a role in the lymphocyte 
homing in the gut, as it is expressed on a subset of memory α4β7+ intestine-homing 
CD4 and CD8 cells and IgA-secreting B-cells (Kim 2005). The selectins mediate 
margination and rolling along the vascular endothelium; integrins and the Ig 
superfamily mediate transendothelial migration. Endothelial leukocyte adhesion 
molecule-1 (E-selectin) is expressed only on endothelial cells, and only after 
activation of inflammatory cytokines. Its expression is up-regulated by interleukin 
(IL)-1, lipopolysaccharide (LPS) and tumor necrosis factor (TNF)-α  (Bevilacqua 
and Nelson 1993; Kansas 1996). 
 
In endothelial cells, E-selectin participates in adhesion of neutrophils and 
eosinophils, and in recruitment of T-cells and monocytes (Bevilacqua and Nelson 
1993; Montefort et al. 1993; Patel et al. 2002). Intercellular adhesion molecule-1 
(ICAM-1) belongs to the Ig superfamily and is widely expressed on vascular 
endothelial cells (Boyd et al. 1988). ICAM-1 expression is induced by inflammatory 
mediators such as interferon (IFN)-γ, IL-1, TNF-α, and LPS. ICAM-1 binds 
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lymphocyte function-associated antigen (LFA)-1 and Mac-1 on leukocytes, leading 
to adhesion of leukocytes to the local endothelium and leukocyte migration to sites 
of inflammation (Montefort et al. 1993; Springer 1994). Levels of the soluble form 
of adhesion molecules E-selectin and ICAM-1 correlates with their expression on 
endothelial cells, and therefore the soluble concentration of these adhesion 
molecules can serve as a marker of an activated immune system, such as in 
inflammatory states (Leeuwenberg et al. 1992; Montefort et al. 1993). 
 
2.3.2 Induction of oral tolerance and the role of gut microbes  
 
Food antigens in small amounts may penetrate though the wall of the gastrointestinal 
tract, but they cause clinical symptoms infrequently, because most individuals 
develop tolerance. Oral administration of antigen leads to a systemic               
antigen-specific state of immunological hyporesponsiveness termed oral tolerance 
(Husby et al. 1994; Husby 2000). The underlying immunologic mechanisms in oral 
tolerance induction are defined only in part, but studies suggest that various  
antigen-presenting cells, especially intestinal epithelial cells, dendritic cells, and 
regulatory T-cells, play a central role (Mowat 2003). The immunologic mechanisms 
in oral tolerance include clonal deletion, anergy, and active suppression, and studies 
suggest that regulatory T-cells mediate these processes (Faria and Weiner 2005). 
Based on animal studies, high exposure to antigens results in anergy/deletion of 
specific T-cells in the gut, and in systemic antigen presentation, suggested to induce 
unresponsiveness of T-cells. Low doses favour the active suppression (Mowat et al. 
1982; Friedman and Weiner 1994; Faria and Weiner 2005). Low doses of antigens, 
presented by APCs, result in the generation of antigen-specific regulatory cells, 
preferentially inducing IL-10-, and TGF-β-secreting T-cells (Miller et al. 1992). 
These immunosuppressive regulatory T-cells inhibit the generation of effector cells 
in lymphoid organs and suppress disease in target organs by releasing suppressive 
cytokines (bystander suppression) (Faria and Weiner 2005). Other factors that affect 
induction of oral tolerance include the nature of the antigen, the frequency of antigen 
exposure (continuous or intermittent), genetic factors, age, and the immunological 
status of the subject (Mowat and Weiner 1999).  
 
In recent years, interest has increased in the role of the intestinal microbiota in 
shaping mucosal immune responses. The intestinal microenvironment has been 
suggested to play an important role in the development of oral tolerance. 
Experimental studies in mice have demonstrated that intestinal colonization plays a 
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vital role in the development of the gut immune system and of oral tolerance (Maeda 
et al. 2001; Sudo et al. 1997). Germ-free mice (GF) have a lower number of T-cells 
in their gut-associated lymphoid tissue compared with specific pathogen-free (SPF) 
mice, a condition related to the failure of oral tolerance induction. A recovery in the 
number of T-cells occurs when mice are colonized by Bifidobacteria infantis and 
Escherichia coli (Maeda et al. 2001). The reconstitution of intestinal microbiota of 
GF mice with Bifidobacterium infantis, one of the predominant bacteria in the 
intestinal microbiota, replaces the susceptibility of Th2 responses to tolerance 
induction (Sudo et al. 1997). These data support the hypothesis that exposure to 
intestinal bacterial strains during infancy provides the mechanism of oral tolerance.  
 
The quality of the indigenous intestinal microbiota may play a role in the 
development of allergic diseases, which often results in a failure in oral tolerance. A 
reduced ratio of bifidobacteria to clostridia has been detectable in infants developing 
atopy (Kalliomäki et al. 2001a). Furthermore, patients with allergic diseases are 
more often colonized with clostridia and staphylococci, and have fewer enterococci 
and bifidobacteria than do non-allergic patients (Björksten et al. 2001; Kalliomäki et 
al. 2001a; Watanabe et al. 2003). Recently, Penders and colleagues (2007) 
demonstrated that differences in gut flora composition precede the manifestation of 
atopic outcomes, early colonization with Escherichia coli was associated with a 
higher risk for developing eczema, and colonization with Clostridium difficile was 
associated with eczema, recurrent wheeze, and allergic sensitization in early infancy. 
 
2.4 Prebiotics 
 
A prebiotic is “a non-digestible food ingredient that beneficially affects the host by 
selectively stimulating the growth and/or activity of one or a limited number of 
bacteria in the colon, and thus improves host health”, (Gibson 1995). The effect of 
prebiotics is linked to several essential conditions: A prebiotic should not be 
hydrolyzed by intestinal enzymes, it should be selectively fermented by beneficial 
bacteria, and this selective fermentation should result in a beneficial effect on health 
or well-being of the host (Guarner 2006).  
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2.5 Probiotic bacteria  
 
2.5.1 Definition   
 
Even in the beginning of the 20th century, Metchnikoff (1910) suggested that 
fermented milk products containing lactobacilli may enhance human health and 
contribute to long life. The term “probiotic” originally denoted any substance or 
organism which contributes to the intestinal microbial balance (Lilly and Stillwell 
1965). The definition of probiotics has evolved since, and the FAO/WHO definition 
is “Live micro-organisms that, when administered in adequate amounts, confer a 
health benefit on the host” (Sanders 2003). Lactobacilli and bifidobacteria are the 
most studied probiotic species, but several other species exhibiting probiotic 
properties are under investigation, including strains of Escherichia coli, 
propionibacteria, enterococci, and yeast (Kopp-Hoolihan 2001; Lodinova-Zadnikova 
et al. 2003). Probiotic bacteria have been isolated from healthy human intestinal 
flora. The human gut is the natural habitat for a large and dynamic bacterial 
community, containing 300 to 500 different species of bacteria, with 10 to 20 genera 
dominating. The dominant genera are Bacteroides, Lactobacillus, Clostridium,  
Bifidobacterium, Eubacterium, Fusobacterium and various anaerobic Gram-positive 
cocci (Harmsen et al. 2000). The primary functions of enteric microbiota include 
metabolic functions, such as fermentation of non-digestible dietary substances, and 
vitamin synthesis; the barrier effect, which protects against pathogens; and trophic 
functions, which control the immune homeostasis of the gut (Guarner 2006). 
Probiotic bacteria may mediate their beneficial effects by modulating the functions 
of enteric microbiota (Rautava and Isolauri 2002). 
 
2.5.2 Effect of probiotics on gut epithelium and intestinal permeability 
 
Intestinal epithelial cells mediate immunological responses against oral antigens. 
Macromolecules penetrate through the tight junctions between surface epithelial 
cells of the intestine. Current evidence supports the idea that intestinal permeability 
is altered as a result of the initial reaction to food allergens, possibly through the 
release of inflammatory cytokines (DeMeo et al. 2002). Intestinal microbes are 
suggested to play a role in the function of immune and epithelial cells. A beneficial 
effect of Lactobacillus casei GG on intestinal permeability appears in suckling rats, 
in which Lactobacillus casei GG reverses a cow´s-milk challenge-induced increased 
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intestinal permeability (Isolauri et al. 1993). In rats, following chronic psychological 
stress, probiotics prevent bacterial translocation and improve intestinal barrier 
function (Zareie et al. 2006). In one clinical study, oral supplementation of 
Lactobacillus rhamnosus and Lactobacillus reuteri for children with atopic 
dermatitis reduced intestinal permeability, and permeability changes were positively 
associated with severity of atopic dermatitis (Rosenfeldt et al. 2004). Probiotic 
bacteria are also suggested to play a role in the recovery of intestinal epithelium. In 
an experimental study,  Lactobacillus rhamnosus GG prevented cytokine-induced 
apoptosis in intestinal epithelial cells (Yan and Polk 2002). In a recent report, 
deleterious effects of TNF-α and IFN-γ such as increased permeability of epithelial 
cells was prevented by probiotic treatment with Streptococcus thermophilus and 
Lactobacillus acidophilus (Resta-Lenert and Barrett 2006). 
 
2.5.3 Effect of probiotics on the innate immune system in vitro  
 
Probiotic bacteria have been shown to modulate innate immune responses in 
experimental settings; their mechanisms of action are, however, largely unknown. 
Stimulation of human peripheral blood mononuclear cells with Lactobacillus 
rhamnosus in vitro promotes the production of IFN-γ, IL-12, and IL-18, the latter two 
being monocyte-derived cytokines (Miettinen et al. 1998). In human macrophage 
cultures, Lactobacillus rhamnosus GG is shown to activate transcription factors 
direcly, leading to NF-κB activation, but also indirectly, via cytokines, leading to 
STAT activation (Miettinen et al. 2000). In one study of probiotic bacteria, 
Lactobacillus casei was shown in mouse spleen cells to induce TNF-α, IL-12, IL-18, 
and IFN-γ and the pathogen-associated molecular pattern receptors TLR2 and Nod2. 
Lactobacillus casei activated innate immunity via NF-κB and p39 MAP kinase 
signalling pathways (Kim et al. 2006). Human intestinal lamina propria mononuclear 
cells, whole blood, or enriched blood dendritic cells were cultured with cell wall 
components of the eight bacterial strains in the probiotic preparation VSL#3 (four 
lactobacilli, three bifidobacteria, and one streptococcal strain). VSL#3 induced IL-10 
secretion of dendritic cells from blood and intestinal tissue, and diminished 
proinflammatory effect of LPS by reducing LPS-induced production of IL-12 and 
maintaining IL-10 production. Different probiotic strains were shown to have distinct 
immunomodulatory effects (Hart et al. 2004). Incubation of human dendritic cells 
isolated from MLNs or PBMCs with Lactobacillus salivarius or Bifidobacterium 
infantis strains results also in differing cytokine responses. PBMC-derived dendritic 
cells secrete TNF-α and IL-12 in response to probiotic stimulation, with IL-10 
secretion of these cells detectable only after Bifidobacterium stimulation. MLN-
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derived DCs secrete IL-10 in response to both Lactobacillus salivarius and 
Bifidobacterium infantis strains (O'Mahony et al. 2006). 
 
Hessle and colleagues (1999) studied the capacity of human intestinal isolates from 
the three Lactobacillus (L.) species dominant in the human gastrointestinal mucosa; 
L. plantarum, L. rhamnosus, and L. paracasei ssp. paracasei, to induce production 
of IL-10 and IL-12 in human peripheral blood mononuclear cells, or monocytes. All 
three Lactobacillus species were potent stimulators of IL-12, while Lactobacillus 
paracasei induced the highest levels of IL-12, and Lactobacillus rhamnosus the 
highest levels of IL-10. These results suggest that mucosa-associated lactobacilli can 
be potent stimulators of IL-10 and IL-12 production, and thus potentially of cell-
mediated immunity if they pass over the gut epithelial barrier and interact with cells 
of the gut immune system. Shida and colleagues (2006) demonstrated the essential 
role of monocytes in Lactobacillus casei-stimulated human peripheral blood 
mononuclear cells. Lactobacillus casei stimulated PBMCs to secrete IL-10, IL-12, 
TNF-α, and IFN-γ, but depletion of monocytes from PBMCs eliminated this 
induction response. Lactobacillus casei was phagocised by monocytes and directly 
stimulated them to secrete IL-10, IL-12, and TNF-α. In addition, after cultivation of 
PBMCs with Lactobacillus casei, natural killer (NK) cell activity and activation 
marker CD69 expression on NK cells increased. When Smits and colleagues (2005) 
studied immunoregulatory properties of different Lactobacillus strains, 
Lactobacillus reuteri and Lactobacillus casei, but not Lactobacillus plantarum 
primed human DCs to drive the development of T-regulatory cells. Lactobacillus 
reuteri and Lactobacillus casei, but not Lactobacillus plantarum, were shown to 
bind C-type lectin DC-specific intercellular adhesion molecule 3-grabbing non-
integrin (DC-SIGN), and the blocking of antibodies to DC-SIGN inhibited the 
induction of T-regulatory cells . 
 
In a murine model, exposure to killed Lactobacillus species induces up-regulation of 
maturation surface markers (MCH class II and B7-2) in dendritic cells, but different 
species of lactobacilli exert very different dendritic cell (DC) activation patterns. 
The authors suggest that lactobacilli may enhance the mechanism of antigen 
presentation (Christensen et al. 2002). Oral Lactobacillus casei administration to 
BALB/c mice results in activation of innate immunity with an increase in the 
specific markers of these cells (CD-206 and TLR-2) (Galdeano and Perdigon 2006). 
Both live and heat-killed preparations of Lactobacillus rhamnosus HN001 enhance 
the phagocytic activity of blood and peritoneal immune cells in mice, but only live 
bacteria are able to enhance gut mucosal antibody response to cholera toxin vaccine  
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(Gill and Rutherfurd 2001), results suggesting that enhanced antibody response may 
be dependent on live bacteria. Sturm and colleagues (2005) analyzed the effects of 
Escherichia coli strain Nissle 1917 on T-cell cycling and expansion. Inhibition of 
proliferation of peripheral blood T cells by Escherichia coli strain Nissle 1917 was 
shown to be TLR-2 dependent.  
 
In a clinical study with Lactobacillus GG, subjects with non-IgE-mediated milk 
hypersensitivity showed up-regulation of phagocytic receptors in neutrophils (CR1, 
FcRI and FcR), and probiotic supplementation reduced the receptor expression. By 
contrast, in healthy subjects, Lactobacillus GG supplementation had 
immunostimulatory effects, detected as an increased receptor expression in 
neutrophils (Pelto et al. 1998). Probiotics were suggested to modulate the 
nonspecific immune response in healthy and hypersensitive subjects differently. In 
another study among healthy adults, the consumption of Lactobacillus adidophilus- 
or a Bifidobacterium bifidum strain-supplemented fermented milk products appeared 
to enhance phagocytic activities of granulocytes and monocytes (Schiffrin et al. 
1995). Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 
5711 raise the proportion of phagocytic cells, including monocytes and neutrophils, 
as well as their phagocytic activity (Olivares et al. 2006). The effects of probiotic 
supplementation (Lactobacillus acidophilus LAVRI-A1; Probiomics) for the first 6 
months of life were evaluated in an allergy-prevention study, with functional 
responses to toll-like receptor (TLR) assessed by use of ligands for TLR2 and 
TLR4/CD14 and also by cytokine responses measured in vitro. In addition, antigen-
presenting cell function (HLA-DR on monocytes, B-cells, and DCs) and IL-12p70 
secretion were detected. Probiotic supplementation failed to alter the early innate 
immune responses evaluated (Taylor et al. 2006a).  
 
2.5.4 Effect of probiotics on antibody production by B-cells 
 
When the effect of probiotic bacteria on B-cell function is evaluated in vaccine 
studies, the immunogenicity of oral rotavirus vaccination is enhanced in infants 
receiving Lactobacillus GG supplementation (Isolauri et al. 1995). In another study, 
a tendency to increased Salmonella-specific IgA levels appeared among subjects 
receiving the vaccine in combination with Lactobacillus GG, but with no significant 
differences in numbers of IgA-, IgG-, and IgM-secreting cells between Lactobacillus 
GG, Lactococcus lactis or placebo groups (He et al. 2000). A recent study showed 
probiotic supplementation (a mixture of Lactobacillus rhamnosus GG, Lactobacillus 
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rhamnosus LC705, Bifidobacterium breve, and Propionibacterium freudenreichii 
spp. shermanii JS) in infants at high risk for atopy as not interfering with antibody 
responses to tetanus, diphtheria, or Hib vaccines; in the placebo group, however, 
protective Hib IgG concentrations occurred less frequently than in the probiotic 
group. Probiotics thus appeared to improve response to Hib immunization 
(Kukkonen et al. 2006). 
 
Probiotic bacteria enhance IgA response to the antigens encountered simultaneously. 
Kaila and colleagues (1992) showed that Lactobacillus GG administration during 
acute rotavirus diarrhoea raises the number of peripheral blood cells secreting IgA 
specific to rotavirus antigen. In children with Crohns disease, oral bacteriotherapy 
with Lactobacillus GG has elevated the number of cells secreting IgA to cow milk 
β-lactoglobulin. However, the immunostimulatory effect of Lactobacillus GG was 
specific for Crohns disease, because no changes occurred in healthy children or in 
children with juvenile chronic arthritis (Malin et al. 1996). In formula-fed infants, 
probiotic supplementation (Lactobacillus GG and Bifidobacterium lactis Bb-12) 
leads to increased cow´s-milk-specific IgA antibody responsiveness. The numbers of 
cow´s-milk-specific IgA-secreting cells were significantly higher in the probiotic 
than in the placebo group (Rautava et al. 2006). 
 
Secretory IgA plays an important role in the defence of the gastrointestinal tract. An 
increase in faecal IgA levels was detectable in healthy Japanese children after 
Bifidobacterium lactis supplementation (Fukushima et al. 1998). Increased faecal 
IgA levels were also detectable after Lactobacillus GG supplementation among 
infants with IgE-associated cow´s milk allergy (Viljanen et al. 2005a). 
 
In one experimental study, Bifidobacterium (B.) bifidum alone, but not Clostridium 
perfringens, significantly induced total IgA and IgM synthesis both by mesenteric 
lymph node (MLN) and by Peyer's patch cells in vitro. The same study investigated 
mucosal antibody production following peroral administration of B. bifidum to mice, 
in which ingested B. bifidum significantly increased the number of IgM-, IgG-, and 
IgA-secreting cells in the culture of both MLN and spleen cells (Park et al. 2002). In 
a mouse model, Lactobacillus acidophilus and Bifidobacterium supplementation has 
enhanced mucosal and systemic IgA responses to cholera toxin presented as an oral 
immunogen (Tejada-Simon et al. 1999). In a murine model of food allergy, 
Lactobacillus casei has suppressed serum IgE and IgG1 responses and systemic 
anaphylaxis (Shida et al. 2002). 
 40 
 
2.5.5 Effect of probiotics on cellular immune responses in vitro 
 
Several in vitro studies demonstrate the effects of probiotic bacteria on T-cell 
responses. Pochard and colleagues (2002) studied the effect of different Lactobacillus 
strains on the cytokine secretion of Staphylococcal enterotoxin         A-(mitogen) or 
Dermatophagoides (D.) pteronyssinus-stimulated peripheral blood mononuclear cells 
(PBMCs). Lactobacillus strains (Lactobacillus plantarum, Lactococcus lactic, 
Lactobacillus casei and Lactobacillus rhamnosus) inhibit     Th2-cytokine (IL-4 and 
IL-5) production of stimulated PBMCs from allergic individuals. In allergic 
individuals sensitized to house dust mite, D pteronyssinus induces a poor IFN-γ 
response, which recovers with incubation with Lactobacilli. The inhibitory mechanism 
is dependent on IL-12 and IFN-γ. Genomic DNA from Bifidobacterium induces 
secretion of the anti-inflammatory interleukin-10 by human PBMCs in vitro (Lammers 
et al. 2003). In vitro incubation of various Lactobacillus strains (Lactobacillus 
rhamnosus 509, Lactobacillus rhamnosus GG, or Lactobacillus bulgaricus) with 
human PBMCs strongly induces IL-1β, IL-6 and TNF-α mRNA expression and 
protein production and weakly induces IL-10 production, while IL-4 production is 
induced by none of these strains. Lactobacillus rhamnosus 509 and Lactobacillus 
rhamnosus GG also induce IL-12 and IFN-γ production (Miettinen et al. 1998). 
Peripheral blood mononuclear cells from healthy donors were co-cultured with 13 
different probiotic strains: This stimulation resulted in significant IL-10 secretion, with 
levels of IL12p70, IL-5 and IL-13 remaining low. Probiotic strains reduce the 
production of Th2-type cytokines of PBMCs. Neutralizing IL-10 production results in 
restoration of Th2 cytokine production and raises levels of  pro-inflammatory 
cytokines such as IL-12p70 and TNF-α (Niers et al. 2005). 
 
Smits and colleagues (2005) studied immunoregulatory properties of different 
Lactobacillus strains, and found Lactobacillus reuteri and Lactobacillus casei to 
prime monocyte-derived dendritic cells to drive the development of T-regulatory 
cells. These cells secrete IL-10 and inhibite the proliferation of bystander T-cells in 
an IL-10-dependent fashion. Lactobacillus GG-degraded peptides from CM reduce 
mitogen-stimulated lymphocyte proliferation and anti-CD3-antibody-induced 
secretion of IL-4 by human PBMCs (Sutas et al. 1996a; b). Lactobacillus paracasei 
subspecies paracasei B21060 suppresses human CD4+ T-cell proliferation after 
anti-CD3/CD2/CD28 activation in vitro (Peluso et al. 2007). 
 
 41 
In animal models, a similar kind of cytokine pattern induced by probiotic bacteria 
occurs. Immunostimulatory oligodeoxynucleotide from Bifidobacterium longum 
suppresses Th2-type immune responses in splenocytes isolated from         
ovalbumin-sensitized BALB/c mice (Takahashi et al. 2006). Lactobacillus 
paracasei, when cultured with mice splenocytes, inhibits the proliferative activity of 
CD4+ T cells and reduces both Th1- and Th2-type cytokines, including IFN-γ, IL-4, 
and IL-5 secretion. In contrast, IL-10 is maintained and TGF-β markedly induced in 
a dose-dependent manner, suggesting the development of T-regulatory cells (von der 
Weid et al. 2001). 
 
In a murine model, treatment with VSL#3 probiotic preparation (probiotic mixture 
containing viable lyophilized bacteria including bifidobacteria, lactobacilli, and 
Streptococcus salivarius) attenuates recurrent Th1-mediated colitis. Probiotics 
ameliorate colitis by inducing IL-10 production and IL-10-dependent regulatory 
CD4+ T cells bearing surface TGF-β in the form of latency-associated protein (Di 
Giacinto et al. 2005). In another murine model of colitis, Lactobacillus salivarius 
and Bifidobacterium infantis have alleviated intestinal inflammation. 
Bifidobacterium infantis reduces IL-12, TNF-α, and IFN-γ secretion, but 
Lactobacillus salivarius only IFN-γ secretion of splenocytes in vitro. The production 
of TGF-β has been maintained in Lactobacillus salivarius, Bifidobacterium infantis 
and placebo groups (McCarthy et al. 2003). Lactobacillus casei reduces skin 
inflammation by inhibiting the priming/expansion of hapten-specific                   
IFN-γ-producing CD8+ effector T-cells in a model of allergic contact dermatitis in 
mice. The inhibitory effect of these probiotics requires the presence of CD4+ T cells 
(Chapat et al. 2004). 
 
Clinical studies of probiotic bacteria among atopic children have suggested that 
probiotics may modify T-cell responses, with contrary results also reported. 
Lactobacillus rhamnosus GG administration to atopic children is associated with 
high serum levels of IL-10. The enhancement of IL-10 production in            
mitogen-induced cultures precedes the rise in serum IL-10 (Pessi et al. 2000). 
Majamaa and Isolauri (1997) found no effects of Lactobacillus GG supplementation 
on secretion of IL-4, IFN-γ, or TNF-α by stimulated (concanavalin A) PBMCs 
among infants with atopic dermatitis (AD) and suspected cow’s milk allergy. 
Rosenfelt and colleagues (2003) found no effects of Lactobacillus rhamnosus 
19070-2 and Lactobacillus reuteri DSM122460 supplementation on secretion of   
IL-2, IL-4, IL-10 or IFN-γ by LPS-PHA-stimulated PBMCs among children with 
AD. Prescott and colleagues (2005) determined the immunological effects of 8-week 
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probiotic Lactobacillus fermentum supplementation to infants with AD; comparing 
cytokine (IL-5, IL-6,  IL-10, IL-13, IFN-γ, and TNF-α) responses of PBMCs to 
allergens – ovalbumin (OVA), beta(β)-lactoglobulin (β-LG), house dust mite 
(HDM)-, and vaccines (tetanus toxoid, TT, diphtheria toxoid, DT), intestinal flora 
(heat-killed Lactobacillus), heat-killed Staphylococcus aureus, Staphylococcus 
aureus enterotoxin B (SEB), and mitogen (phytohaemaglutinin, PHA). The 
administration of probiotics was associated with a significant increase in Th1-type 
cytokine IFN-γ responses to PHA and SEB. The increase in IFN-gamma responses 
to SEB was directly proportional to the decrease in the severity of AD. IL-13 
responses to ovalbumin were significantly reduced in children receiving probiotics 
after 8 weeks, but with no other effects on allergen-specific responses. No effects on 
vaccine-specific responses occured, and no responses to any of the stimuli assessed.  
 
In a double-blind crossover study, a combination of two probiotic Lactobacillus 
strains (lyophilized Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri 
DSM 122460) was given for 6 weeks to 1- to 13-year-old children with AD. No 
significant changes in the production of IL-2, IL-4, IL-10, or IFN-γ by                     
LPS-PHA-stimulated PBMC appeared after probiotic or placebo supplementation 
(Rosenfeldt et al. 2003). Moreover, another randomized, placebo-controlled study of 
the effects of Lactobacillus (Lactobacillus rhamnosus or Lactobacillus GG) 
supplementation to infants with AD and suspected CMA showed no immunological 
effects of probiotic bacteria. Probiotic supplementation for 3 months to infants did 
not affect secretion of IL-4, IL-5, or IFN-γ by stimulated (concanavalin A or 
antiCD3/anti-CD28) PBMCs (Brouwer et al. 2006).  
 
In their allergy-prevention study, Taylor and colleagues (2006c) studied the effects 
of probiotic supplementation for the first 6 months of life on allergen- and         
vaccine-specific immune responses among atopy-prone infants. Cytokine (IL-5,    
IL-6, IL-10, IL-13, TNF-α, or TGF-β) responses to TT, HDM, OVA, β-LG, SEB, 
and PHA in vitro by ELISA were detected at age 6 months. Infants in the probiotic 
group showed reduced production of IL-5 and TGF-β in response to polyclonal 
(SEB) stimulation and lower IL-10 responses to TT vaccine antigen compared with 
that of the placebo group. No significant effect of probiotics was found on either 
type 1 (Th1) or type 2 (Th2) T-helper cell responses to allergens or other stimuli, 
except reduced TNF-α and IL-10 responsiveness to HDM allergens in the probiotic 
group. The study suggested that probiotics may have immunomodulatory effects on 
vaccine responses. 
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2.5.6 Clinical effects of probiotics on atopy and allergic diseases in children 
 
Majamaa and Isolauri (1997) were the first to show the clinical effect of probiotic 
bacteria among atopic infants. In a randomized, double-blinded study, infants with 
atopic eczema and suspected CMA received Lactobacillus GG supplementation. 
They started a cow´s milk elimination diet, and a placebo group received an 
extensively hydrolyzed whey formula alone. The probiotic group received the same 
formula fortified with Lactobacillus GG for one month. However, the study 
population was small (n = 31), RAST for CM was positive in 37%, and SPT for CM 
was positive in 30% of infants. After one month’s intervention, a significant 
improvement occurred in SCORAD score in the probiotic group, but not in the 
placebo group. Faecal TNF-α and α -1-antitrypsin concentrations decreased in these 
infants in parallel. Another study involved the effect of probiotic bacteria on atopic 
eczema among atopic infants with eczema during exclusive breastfeeding (Isolauri 
et al. 2000).  After 2 months’ treatment, a significant improvement in atopic eczema 
occurred in infants on probiotic-supplemented formulas, Bifibobacterium lactis     
Bb-12 or Lactobacillus GG when compared with eczema in infants who received 
unsupplemented formulas. Levels of serum-soluble CD4 and urine eosinophilic 
cationic protein X fell in parallel (Isolauri et al. 2000). The same group studied the 
effects of viable Lactobacillus GG, inactivated Lactobacillus GG, and placebo in 
infants with atopic eczema and cow´s milk allergy (Kirjavainen et al. 2003). In all 
groups, severity scoring of atopic dermatitis (SCORAD) scored decreased during the 
treatment, but the decrease tended to be greater in the viable Lactobacillus GG 
group than in the placebo group (Kirjavainen et al. 2003). 
 
In a double-blind crossover study, Rosenfelt and colleagues (2003) demonstrated 
that Lactobacillus rhamnosus 19070-2 and Lactobacillus reuteri DSM122460 
improved atopic eczema in children, but total SCORAD index did not change 
significantly. Interestingly, this treatment response was more pronounced in patients 
with IgE-associated disease. During the treatment, serum eosinophilic cationic 
protein levels decreased. Our group studied the clinical effects of probiotics in 
infants with eczema who were suspected of having cow´s milk allergy. These infants 
received Lactobacillus GG, a mixture of four probiotic strains, or placebo 
concomitantly with an elimination diet. No differences in SCORAD index emerged 
immediately after 4 weeks’ treatment, but a greater reduction in SCORAD was 
detectable 4 weeks after the treatment in IgE-sensitized infants receiving 
Lactobacillus GG when compared with the placebo group (Viljanen et al. 2005b). 
Weston and colleagues (2005) showed the positive effect of Lactobacillus 
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fermentum on atopic dermatitis in children aged 6 to 19 months. Most of the 
children both in probiotic (71%) and placebo (71%) groups reacted with elevated 
IgE antibody levels to a food mix. Probiotic supplementation for 8 weeks reduced 
SCORAD index significantly in the probiotic group, but not in the placebo group. 
 
Recently, Brouwer and colleagues (2006), studying the effect of Lactobacillus 
rhamnosus and Lactobacillus GG on atopic dermatitis in infancy, found no clinical 
effects from 3 months’ probiotic supplementation on symptoms of infantile atopic 
dermatitis. Their research protocol was, however, different from that in previous 
studies of probiotics, whereas probiotic supplementation was started after baseline 
period (diagnostic procedures for CMA and instructions on the skin care) and most 
of the infants had specific IgE levels to six antigens (CM, egg white, soy, peanut, 
cod, and wheat) tested below < 0.35 kU/l, implying that the effects were being 
studied mostly on children with non-IgE associated eczema.  
 
Isolauri’s group were the first who studied the preventive effect of Lactobacillus GG 
supplementation on early atopic disease among infants at high risk for atopic diseases 
(Kalliomäki et al. 2001b). Lactobacillus GG was given to mothers daily for 2 to 4 
weeks before expected delivery, and postnatally for 6 months to their infants or to the 
breastfeeding mothers. At age 2 years, the frequency of atopic eczema in the probiotic 
group was half that of the placebo, but probiotics had no effect on severity of atopic 
dermatitis, as measured by the SCORAD index. No differences appeared in specific 
IgE levels or skin prick test (SPT) results (Kalliomäki et al. 2001b). In the same study, 
TGF-β2 concentrations in the milk of mothers receiving Lactobacillus GG were 
significantly higher than in the placebo group, and the risk for eczema during the first 
2 years of life was reduced in infants whose mothers received Lactobacillus GG for 3 
months after delivery (Rautava et al. 2002). This study was later extended to study the 
potential of Lactobacillus GG to prevent atopic eczema at age 4. Results suggested 
that the preventive effect of Lactobacillus GG on atopic eczema extends beyond 
infancy: Of 53 children in the Lactobacillus GG group, only 14 had developed atopic 
eczema, compared with 25 of 54 receiving placebo. IgE-sensitization did not differ 
between these groups (Kalliomäki et al. 2003). 
 
Taylor and colleagues (2007) studied the role of Lactobacillus acidophilus  
(LAVRI-A1) supplementation for the first 6 months of life in atopic dermatitis at 
ages 6 and 12 months and sensitization at age 12 months. Risk for atopic dermatitis 
was not reduced, and probiotic supplementation with Lactobacillus acidophilus was 
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associated with increased allergen sensitization in high-risk infants. By contrast, 
Abrahamsson and colleagues (2007) reported recently that Lactobacillus        
reuteri-treated infants have less IgE-associated eczema at age 2 years, although no 
preventive effect of probiotics on infant eczema could be confirmed. Interestingly, 
the mothers were not supplemented with a probiotic product in the study of Taylor 
and colleagues, but in the other prevention studies the probiotic supplementation to 
the mothers was started during pregnancy. 
 
2.5.7 Safety  
 
In 1990, Lactobacillus rhamnosus GG was introduced into some dairy products in 
Finland. During a rapid increase in consumption of dairy products containing 
probiotics, the incidence of lactobacillus bacteremia did not increase in Finland and, 
in fact had been very rare (Salminen et al. 2002). Clinical studies have demonstrated 
that probiotic products containing lactobacilli and bifidobacteria are well tolerated in 
infants and children (Millar et al. 1993; Majamaa and Isolauri 1997; Pedone et al. 
1999; Rosenfeldt et al. 2003; Viljanen et al. 2005b). Only one study has shown an 
association of consumption of heat-inactivated Lactobacillus rhamnosus GG with 
adverse gastrointestinal symptoms and diarrhoea (Kirjavainen et al. 2003). In a 
recent study, acute otitis media tended to be, and spitting-up was more common in a 
Lactobacillus reuteri group than in the placebo group of infants, but no severe 
adverse events were reported (Abrahamsson et al. 2007). 
 
Lactobacilli and bifidobacteria cause infection in humans extremely rarely. Most of 
the rare cases occur in patients with severe conditions such as immunosuppression, 
prior prolonged hospitalization, or surgical interventions (Borriello et al. 2003; 
Salminen et al. 2004a). Prospective studies have shown that probiotics are safe in 
immunocompromised adults and children with HIV (Cunningham-Rundles et al. 
2000; Salminen et al. 2004b). In another immunocompromised population, preterm 
neonates, probiotics have reduced the incidence and severity of necrotizing 
enterocolitis, with no secondary probiotic infections (Bin-Nun et al. 2005; Lin et al. 
2005). Recently the safety of probiotics was evaluated in a scientific review with the 
conclusion that the benefits of probiotics outweigh the potential danger of sepsis, 
although anecdotal reports of sepsis do exist (Hammerman et al. 2006). Probiotic 
supplementation may therefore be a risk factor for immunocompromised patients and 
can not be recommended for patients with severe conditions. Documentation of safety 
is an important reason why probiotics should be defined strains, and thus so far, 
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several Lactobacillus strains are known to be safe when orally administered to non-
immunocompromized infants, but other species of probiotics (i.e., Escherichia coli, 
Propionibacteria, Enterococci) are not as yet evaluated comprehensively for safety.                                   
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3 AIMS OF THE STUDY 
Allergic diseases in early infancy are manifestations of a failure of tolerance. The 
aims of the study were to investigate the immunological effects of probiotic bacteria 
in prevention and treatment of atopy and allergic diseases and to characterize the 
immunological features of cord blood mononuclear cells of infants at high genetic 
risk for allergic diseases. The specific aims of the individual studies are listed below: 
 
 
1. To investigate the effects of Lactobacillus rhamnosus GG (LGG) and a 
mixture of four bacterial species (MIX) on PBMC responses in vitro in 
infants with eczema and suspected cow´s milk allergy. 
 
2. To study the immunological responses of PBMCs in vitro in infants with 
eczema and with cow´s milk allergy (IgE-, or non-IgE-associated). 
 
3. To define the immunologic and inflammatory effects of probiotic bacteria 
in the peripheral blood of infants with eczema and with cow’s milk allergy.  
 
4. To examine the effects of a mixture of four bacterial species combined with 
prebiotic oligosaccharides on the immunologic and inflammatory response 
in allergy-prone infants and to analyze the associations of these responses 
with an allergic phenotype at age 2 years. 
 
5. To investigate T-cell associated cytokine responses and T-cell polarization 
associated IL-4R and IL-12R expressions, and the respective transcription 
factors GATA-3 and T-bet in stimulated CBMCs of atopy-prone infants.  
 
6. To investigate the associations between CBMC stimulation responses and 
allergic diseases, and IgE-sensitization at age 2 years.  
 
 48 
4 MATERIALS AND METHODS 
4.1. Flora1 study (I-II) 
 
4.1.1 Study protocol  
 
The study population comprised infants participating in a clinical study on the effects of 
probiotics on symptoms of atopic dermatitis in infants between November 1999 and 
March 2002 at the Skin and Allergy Hospital, University of Helsinki. Of 230 infants, 
132 were randomly selected from the Skin and Allergy Hospital for the immunological 
study. These infants were under 12 months of age, had eczema, and were suspected to 
have cow`s milk allergy. In a randomized, double-blind study design, concomitantly 
with an elimination diet and skin treatment, Lactobacillus rhamnosus GG (ATCC 
53103) 5 x 109 colony-forming units (cfu), or a mixture of four  probiotic strains (MIX): 
LGG 5 x 109 cfu, Lactobacillus rhamnosus LC705 5 x 109 cfu, Bifidobacterium breve 
Bbi99 2 x 108 cfu, and Propionibacterium freudenreichii ssp. shermanii JS 2 x 109 cfu, 
or placebo: the inert matrix material, microcrystalline cellulose, was given for 4 weeks to 
the infants. Blood samples were collected before and after the treatment. The ethics 
committee of the Hospital for Children and Adolescents, University of Helsinki, 
approved the study protocol. One parent of each infant gave written, informed consent 
for sample collection and analyses. 
 
On the first visit, infants and their breast-feeding mothers began a CM-free diet. 
Infants started on extensively hydrolyzed whey formula (EHF; Peptidi-Tutteli, Valio 
Ltd, Helsinki, Finland). They were randomized to receive a probiotic (LGG or MIX) 
or placebo product. Concomitantly, topical skin-treatment instructions were given to 
the parents. Infants were followed for up to 12 weeks by the study protocol shown 
below (Fig 2). 
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first second third fourth fifth      Visit  
________________________________________________________       Interval      
      4 weeks               4 weeks             1-2 weeks                 1-2 weeks  
--------------------- 
.................................................................................................................. 
Pre-treatment          Post-treatment  Post-challenge        Post-challenge                    Diagnosis 
 
-------- LGG, MIX or placebo  Double-blind placebo-controlled  
   cow’s-milk challenge 
.......... Cow’s milk elimination 
 
Figure 2. Study protocol 
 
4.1.2 Diagnosis of cow’s milk allergy  
  
DBPC cow’s milk challenge was performed after an 8-week cow’s milk-elimination 
diet. The active formula, an adapted cow’s milk (CM) formula (Tutteli®) mixed 
with the EHF (1:2), or placebo formula (EHF alone) was first applied to the skin and 
then given orally in quantities of 2, 10, 50, and 100 ml at 30-minute intervals. 
Symptom-free infants continued to receive the same formula 4 to 6 dl daily at home 
for the next 4 days. After a wash-out period of 2 to 9 days, the challenge formula 
was changed and the procedure repeated.  Thereafter, a decision as to the 
symptomatic challenge period was made, and the milk code was opened.  CMA was 
diagnosed in infants who showed urticaria, clear worsening of atopic dermatis, 
vomiting, diarrhoea, wheezing, allergic rhinitis, or conjunctivitis during the 
challenge with CM-containing formula (Table II). 
 
4.1.3 Skin prick test (SPT) and serum IgE measurements 
 
At the first visit, SPTs were performed with commercial allergen extracts of egg 
white (1000 IC/ml; Alyostal prick test®, Stallergenes SA, Antony, France), cat, dog, 
and birch (10 HEP; Soluprick®, ALK-Abelló, Hørsholm, Denmark) according to the 
standard technique (Dreborg et al. 1989). Duplicate tests were performed with      
fat-free CM: a panel of 10 widely used, commercially available adapted CM, 
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extensively hydrolysed, amino acid- and soy protein-based infant formulas, and 
cereal grains and purified gliadin. Histamine dihydrochloride (10 mg/ml) served as a 
positive control and the solvent (glycerin) as a negative control (ALK-Abellò). The 
wheal size was calculated as the mean of the largest diameter and its orthogonal 
diameter at 15 minutes. Reactions were considered positive if the mean diameter of 
the wheal was > 3 mm greater than that of the negative control. Serum IgE levels 
(specific to cow’s milk, or wheat) were analysed in peripheral blood samples by 
immunoassay (ImmunoCAP® system, Pharmacia Diagnostics, Uppsala, Sweden). 
 
4.1.4 Diagnostic criteria 
 
Eczema was defined as dry skin with an itchy skin condition and eczema at typical 
sites and included both nonatopic and atopic eczema (Williams et al. 1994). Infants 
with a positive SPT to any antigen tested or any specific IgE concentration > 0.7 
kU/l were considered to have IgE-associated dermatitis (atopic eczema). Eczema 
was defined as non-atopic eczema if none of the SPTs were positive, and all specific 
IgE concentrations were < 0.7 kU/l according to the new nomenclature (Johansson 
et al. 2004) (Table I). Infants with a positive CM challenge and a positive SPT to 
any antigen tested or to any specific IgE concentration > 0.7 kU/l were considered to 
have IgE-associated CMA (Table II). CMA was IgE-mediated if the CM challenge 
was positive and the SPT to CM was positive or CM-specific IgE concentration was 
> 0.7 kU/l.  Non-IgE-associated CMA was diagnosed if the CM challenge was 
positive, and none of the SPTs were positive, and all specific IgE concentrations 
were < 0.7 kU/l (Table II). 
 
4.2. Flora2 study (III-IV) 
 
4.2.1 Study protocol  
 
The study population comprised infants participating in a clinical study on the role 
of probiotics, performed between November 2000 and March 2003 in the prevention 
of allergic diseases, at the Skin and Allergy Hospital of Helsinki University Central 
Hospital: 1223 mothers were randomized into this double-blind placebo-controlled 
study, and 925 of their infants completed the study. Cord blood samples (n = 98) 
were randomly selected from maternity hospitals in Helsinki for the immunological 
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study of cord blood. From another 98 infants at age 6 months randomly selected at 
the Skin and Allergy Hospital of Helsinki University Central Hospital blood samples 
were drawn for the immunological study of probiotic bacteria and response to 
vaccinations (Kukkonen et al. 2006). Peripheral blood samples at age 6 months from 
these 98 infants were analysed. All infants were born after normal deliveries (> 37 
gestational weeks) and each had a high genetic risk for allergy; at least one parent 
had doctor-diagnosed atopic eczema, asthma, or allergic rhinitis. 
 
Mothers were randomized to receive a mixture of four bacterial species and an 
oligosaccharide product (Valio LtD, Helsinki, Finland) or placebo in a            
double-blinded manner. The bacterial species in each capsule were Lactobacillus 
rhamnosus GG (ATCC 53103) 5 x 109 cfu, Lactobacillus rhamnosus LC705 5 x 
109 cfu, Bifidobacterium breve Bbi99 2 x 108 cfu, and Propionibacterium 
freudenreichii ssp. shermanii JS (DSM 7076) 2 x 109 cfu. Mothers received these 
products as capsules twice a day for one month before delivery, and their infants 
received one capsule a day and 20 drops (0.8 g) of prebiotic                            
galacto-oligosaccharides once daily for the first 6 months. The placebo group 
received placebo capsules, the inert matrix material being microcrystalline cellulose, 
with a glucose syrup. 
 
Infants of mothers randomized to the probiotic group received the probiotic 
preparation with galacto-oligosaccharides, and infants of mothers randomized to the 
placebo group received the placebo product. The ethics committee of the Hospital 
for Children and Adolescents, University of Helsinki, approved the study protocol. 
Written informed consent was obtained from parents. An external evaluator made 
the statistical analyses between the probiotic and placebo groups, since the 
randomization code was not opened in this study. The study protocol is shown in 
Figure 3. 
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 first second          third    Visit  
________________________________________________________                            
    
----------------------------------------- 
.................................................................................................................. 
Birth 3 months 6 months  2 years 
↑                                ↑                                      ↑ 
Cord blood  SPT egg white  SPT to 8 allergens 
  Peripheral blood  Peripheral blood 
 
– – – – – Mixture of bacterial strains or placebo 
Figure 3. Study protocol 
 
4.2.2 Clinical follow-up and diagnoses 
 
At 3 and 6 months, and at 2 years, a pediatrician examined the infants, and recorded 
symptoms and signs of atopic diseases. Eczema was defined as an itchy dry skin 
condition with eczema at typical sites and included both nonatopic and atopic 
eczema (Williams et al. 1994). Infants with a positive SPT to any antigen tested or 
any specific IgE concentration > 0.7 kU/l were considered to have atopic eczema. 
Eczema was defined as non-atopic if none of the SPTs were positive, and all specific 
IgE concentrations were < 0.7 kU/l according to the new nomenclature (Johansson 
et al. 2004) (Table I). Food allergy was defined as a positive open food challenge 
after a successful elimination diet (Bruijnzeel-Koomen et al. 1995) (Table II). 
Asthma was defined as two or more doctor-diagnosed wheezy episodes 
accompanied by persistent cough or exercise-induced symptoms between the 
episodes (National Asthma Education and Prevention Program 2000) (Table II). 
Allergic rhinitis was based on typical symptoms, and a positive SPT to pollens or 
animal dander or both as in diagnostic criteria of the International Rhinitis 
Management Group (1994) (Table II). Children with a positive SPT to any antigen 
tested or any specific IgE concentration > 0.7 kU/l at age 2 years were considered to 
be IgE-sensitized to allergen (Table I). Children with eczema, asthma, food allergy, 
or allergic rhinitis were considered to have allergic disease. Children with allergic 
disease and a positive SPT to any antigen tested or any specific IgE concentration > 
0.7 kU/l were considered to have IgE-associated disease. (Table II). In the control 
group, children had no signs or symptoms of an atopic disease nor any indication of 
allergen sensitization (i.e., negative SPT, specific IgE < 0.7 kU/l). 
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4.2.3 Skin prick test (SPT) and specific IgE measurements 
 
Skin prick tests were performed with commercial allergen extracts of egg white at 
ages 6 and 24 months (1000 IC/ml; Stallergenes); and birch, timothy, cat, dog, (10 
HEP; ALK-Abellò), fish (1000 IC/ml; Stallergenes), and commercial CM and wheat 
grains (diluted in 0.9% NaCl) at age 2 years according to the standard technique 
(Dreborg et al. 1989) Histamine dihydrochloride (10 mg/ml) served as a positive 
control and the solvent (glycerin) as a negative control (ALK-Abellò). The wheal 
size was calculated as the mean of the largest diameter and its orthogonal diameter 
at 15 minutes. Any mean wheal diameter > 3 mm greater than the negative control 
was considered positive. At the  2-year visit, plasma IgE levels (specific to egg 
white, cow’s milk, cat, dog, timothy, birch) were analysed from the peripheral blood 
samples by solid phase fluorescent immunoassay (ImmunoCAP® system, 
Pharmacia Diagnostics, Uppsala, Sweden). 
 
Table I. Diagnositic criteria of eczema and IgE-sensitization in Flora1 and Flora2 studies 
____________________________________________________________________ 
Eczema = non-atopic and atopic eczema An itchy skin condition with eczema at 
= atopic eczema dermatitis syndrome (AEDS) typical sites plus > 3 of the following: 
history of atopic disease in the family, 
dry skin during the last year, history of 
eczema, or visible eczema involving 
typical sites (Williams et al. 1994) 
 
IgE-associated eczema = atopic eczema  Eczema (Williams et al. 1994) and 
= IgE-associated dermatitis  a positive SPT to any antigen tested or 
any specific IgE concentration 
> 0.7 kU/l   
 
Non-IgE-associated eczema = non-atopic eczema  Eczema (Williams et al. 1994) with 
none of SPTs positive, and all specific 
IgE concentrations < 0.7 kU/l  
 
IgE-sensitization  Positive SPT to any antigen tested or 
any specific IgE concentration > 0.7 
kU/l 
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Table II. Diagnostic criteria of allergic rhinitis, asthma, food allergy, CMA, and 
IgE-associated disease in Flora1 and Flora2 studies 
____________________________________________________________________ 
Allergic rhinitis Nasal discharge, blockage, and 
sneeze/itch recurrently during antigen 
contact, and a SPT to pollens or animal 
dander or both (International Rhinitis 
Management Group 1994) 
Asthma Two or more doctor-diagnosed wheezy 
episodes accompanied by persistent 
cough or exercise-induced symptoms 
between the episodes (National Asthma 
Education and Prevention Program 
2000) 
Food allergy Positive food challenge after a 
successful elimination diet (Bruijnzeel-
Koomen et al. 1995), (DBPC food 
challenge in Flora1 study and open 
food challenge in Flora2 study) 
CMA  positive CM challenge  
 
IgE-mediated CMA positive CM challenge and a positive 
SPT to CM or CM-specific IgE 
concentration  > 0.7 kU/l  
IgE-associated CMA  positive CM challenge and a positive 
SPT to any antigen tested or to any 
specific IgE concentration > 0.7 kU/l 
Non-IgE–associated CMA  Positive CM challenge, and none of the 
SPTs positive, and all specific IgE 
concentrations  < 0.7 kU/l 
IgE-associated disease Allergic disease (astma, allergic 
rhinitis, food allergy, or eczema) and a 
positive SPT to any antigen tested or 
any specific IgE concentration > 0.7 
kU/l  
_______________________________________________________________________________ 
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4.3. Laboratory methods  
 
4.3.1. In vitro stimulation of PBMCs and CBMCs (I, IV) 
 
In Study I, peripheral blood mononuclear cells (PBMC) were obtained by        
Ficoll-Hypaque (Pharmacia Biosciences, Uppsala, Sweden) centrifugation of the 
heparinized blood. PBMCs (2 x 106 / 2 ml) in RPMI 1640 medium (GibcoBRL, 
Gaithersburg, MD, USA) containing 5% AB serum (Finnish Red Cross Blood 
Transfusion Service, Helsinki, Finland) and 1% L-glutamine (GibcoBRL) were 
cultured and stimulated with monoclonal OKT3 (anti-CD3) antibody (1 μg/well) 
(R&D Systems Inc. Minneapolis, MN, USA) -coated plates (Nunc, Roskilde, 
Denmark) in the presence of soluble anti-CD28 antibody (2 μg/well) (Becton 
Dickinson immunocytometry systems (BD), San Jose, CA, USA). Control cultures 
were incubated similarly without stimulation. After 24 hours, a supernatant sample  
(0.5 ml/well) was collected for further enzyme-linked immunosorbent assay 
(ELISA) analysis, and Brefeldin A (10 μg/ml) (Sigma, St. Louis, MO, USA) was 
added to the culture media. Cells were collected for FACS analysis after a 
incubation of 40 to 42 hours.  
 
In Study IV, cord blood samples were collected from placental veins into sterile 
sodium heparinized tubes. Cord blood mononuclear cells (CBMCs) were obtained 
by Ficoll-Hypaque centrifugation of the cord blood (Pharmacia). CBMC were 
suspended (106 cells/ml) in RPMI-1640 (GibcoBRL) containing 5% AB-serum 
(Finnish Red Cross Blood Transfusion Service) and 1% L-glutamine (GibcoBRL) 
and incubated for 72 hours at 37°C in 96-well cell-culture plates (Nunc)              
(200 μl/well) in four parallel wells with phytohaemagglutinin (PHA) (5μg/ml) 
(Sigma), beta-lactoglobulin (200 μg/ml) (Sigma), or medium alone. The culture 
supernatants and CBMCs were collected after 72 hours incubation and were stored 
at -70°C for subsequent analysis. 
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4.3.2 Determination of cytokine levels 
 
4.3.2.1 Cytokines in in vitro studies (I, IV) 
 
IFN-γ, IL-5, IL-4, IL-12, and IL-13 concentrations in culture supernatants were 
measured with ELISA. Microtiterplates (Nunc) were coated with monoclonal     
anti-human IFN-γ-antibody (Lot CD48432, Endogen, Woburn, MA, USA) (2 µg/ml, 
50 µg/well). Supernatants (100 µl/well) and standards (100 µl/well) were incubated 
for 2 hours at room temperature. Biotinylated anti-human IFN-γ monoclonal 
antibody (Lot CD47529, Endogen) was added (0.25 µg/ml, 50 µl/well).                
AP-Streptavidin Conjugate (Zymed Laboratories, San Francisco, CA, USA) served 
as the substrate. Dilutions of recombinant human IFN-γ (Lot M070524, BD 
Pharmingen) were used to create a standard curve (detection limit was 8 pg/ml).   
IL-5 concentrations were measured by the same protocol, using a purified rat      
anti-mouse/human IL-5 monoclonal antibody at 1 µg/ml (Lot M049743, 
Pharmingen) for coating, and biotinylated rat anti-human IL-5 monoclonal antibody 
at 0.5 µg/ml (Lot M057221, Pharmingen) for detection. Dilutions of recombinant 
human  IL-5 (Lot M021519, Pharmingen) were used to create a standard curve 
(detection limit was 15 pg/ml). IL-4 concentrations were determined with a human 
IL-4 ELISA Kit (Pelikine CompactTM, Amsterdam, Netherlands), detection limit 
0.6 pg/ml. Total IL-12 protein levels were measured by high-sensitivity sandwich 
ELISA (Quantikine® HS, R&D Systems, Abingdon, UK) (detection limit 0.6 
pg/ml). IL-13 concentrations were determined with a human IL-13 ELISA Kit 
(Pelikine CompactTM), detection limit 0.5 pg/ml. All tests were performed 
according to the manufacturer`s instructions, and were performed in duplicate. The 
intensity of the color was measured with multiscan MS version 8.0 (Labsystems Oy, 
Helsinki, Finland). 
 
In Study I, PBMC were fixed with 4% paraformaldehyde, suspended in 0.5% bovine 
serum albumin in phosphate-buffered saline (BSA-PBS) and incubated with 
antibodies to surface markers such as CD4 (BD) or CD69 (BD). PBMCs were 
permeabilized with BD FACS Permeabilizing Solution and stained with 
phycoerythrin-conjugated mAbs to IL-4 (BD), IFN-γ (BD), or IL-5 (Serotec Co, 
Oslo, Norway). CD4+ lymphocytes (n = 10 000) were collected in a FACScan flow 
cytometer (FACSCalibur, BD). Analysis gates were set on  CD4+ lymphocytes 
according to forward and sideward scatter properties, and results were expressed as 
percentage of cytokine-producing CD4+ cells. 
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4.3.2.2 Cytokine  levels in plasma  (II-IV) 
 
Plasma samples from peripheral and cord blood were obtained by Ficoll-Hypaque 
(Pharmacia) centrifugation of the heparinized blood. Tumor necrosis factor-α   
(TNF-α), interferon-gamma (IFN-γ), interleukin (IL)-2 (IL-2), IL-4, IL-6, and IL-10 
concentrations were determined by cytokine bead assay (CBA) (CellQuest software, 
BD). The cytokine capture beads were incubated with standards or plasma samples 
and were mixed with the detection antibodies (PE-conjugated) according to the 
manufacturer's instructions (BD Biosciences Pharmingen, San Diego, CA, USA). 
Cytokine concentrations were measured on a FACScan flow cytometer 
(FACSCalibur, BD) (detection limit 2.6 pg/ml for IL-2 and IL-4, 3.0 pg/ml for IL-6, 
2.8 pg/ml for IL-10 and TNF-α, and 10 pg/ml for IFN-γ). Analysis was done with 
BD CBA analysis software MAC OS version 9. 
 
TGF-β1 and TGF-β2 concentrations in the plasma samples were measured with 
human TGF-β1 and TGF-β2 ELISA kits (Quantikine®, R&D Systems) according to 
manufacturer`s instructions (detection limits were 84 pg/ml, and 54.6 pg/ml 
respectively). 
 
4.3.3 C-reactive protein (II-III) 
 
In the Flora1 study (II) CRP concentrations in plasma samples were measured by an 
immunoturbidimetric ultrasensitive CRP assay (Orion Diagnostica, Espoo, Finland) 
according to manufacturer`s instructions, detection limit 0.29 μg/ml. In the Flora2 
study (III), CRP concentrations in plasma samples were determined with human C-
reactive protein Instant ELISA (Bender MedSystems, Vienna, Austria) according to 
manufacturer's instructions (detection limit 78 pg/ml). 
 
4.3.4 Adhesion molecules (II) 
 
The soluble (s) ICAM-1 and sE-Selectin protein levels in plasma were measured 
with commercial sandwich ELISA kits (Parameter®, R&D Systems) according to 
manufacturer`s instructions. Detection limits were 37.2 ng/ml and 10.6 ng/ml.  
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4.3.5 Antibodies and immunoglobulins (I-IV) 
 
Quantities of cow`s milk (CM)-, alpha (α) -casein-, and ovalbumin (OVA) -IgA and 
-IgG antibodies, and total IgA in plasma samples were measured with ELISA. For     
total IgA, the microtiter plates (Nunc) were coated overnight at +4°C with 
polyclonal rabbit anti-human IgA (No. A-0262, DakoCytomation, Glostrup, 
Denmark) at a dilution of 1 µl/ml in 0.06 M NaHCO3, pH 9.6 (100 µl/well), for 
CM-IgA ELISA with an adapted CM-formula (Tutteli®) at a dilution of 2 µl/ml in 
0.06 M NaHCO3, pH 9.6 (100 µl/well), for α-casein-IgA ELISA with casein from 
bovine milk  (No. C-6780, Sigma) at a concentration of 2 µg/ml in PBS (100 
µl/well), and for ovalbumin-IgA with albumin from chicken egg-white (A-5378, 
Sigma) at a concentration of 10 µg/ml (100 µl/well). Plasma samples (100 µl/well) 
and standards (100 µl/well) were incubated overnight at +4°C. Alkaline 
phosphatase-conjugated affinipure rabbit anti-human serum IgA (No. 309-055-011 
Jackson ImmunoResearch Laboratories, Inc. Suffolk, UK) was added at a 
concentration of 0.05 nmol/ml (100 µl/well). SIGMAFAST TM p-nitrophenyl 
phosphate tablets (No. N-2770, Sigma), which were dissolved in deionized water 
(0.05 mg/ml), served as the substrate (100 µl/well). Dilutions of pooled serum 
samples with high levels of antibodies served to create a standard curve. Results of 
CM-IgA analysis were compared to those from a serum sample with a high level of 
antibodies, and expressed as a 10-2 -fold percentage in relation to the reference 
serum. Results of the other analysis were compared to a serum sample with a high 
level of antibodies, and expressed as a percentage in relation to the reference serum. 
Quantities of CM-IgG, alpha (α) -casein-IgG, and ovalbumin-IgG in plasma samples 
were measured in the respective ways as in IgA-analyses, with alkaline  
phosphatase-conjugated affinipure rabbit anti-human IgG (No. 309-055-018 Jackson 
ImmunoReseach Laboratories, Inc.) serving as the conjugate. All tests were 
performed in duplicate. The intensity of the color was measured with multiscan MS 
version 8.0 (Labsystems Oy). 
 
Concentrations of plasma and cord blood total IgE, and plasma-specific IgE      (CM-, 
wheat-, egg-white-, cat-, dog-, timothy-, and birch-IgE) were measured by the Pharmacia 
UniCAP fluoroenzyme immunoassay (ImmunoCAP® system, Pharmacia diagnostics) 
according to manufacturer`s instructions with a detection limit of 0.35 kU/l. 
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4.3.6 Quantitive real-time (RT) PCR (IV) 
 
The mRNA expression of GATA-3, T-Bet, IL-4 receptor, and IL-12 receptor were 
detected by quantitative real-time RT PCR from PHA-stimulated and non-stimulated 
cord blood mononuclear cells. Total RNA (tRNA) was extracted from frozen          
(-70ºC), lyzed cells by the Total Gen Elute Mammalian RNA Kit (Sigma). A reverse 
transcription reaction was carried out in a final volume of 20 μl by use of TaqMan 
Reverse Transcription reagents (Applied Biosystems, Foster City, CA, USA). The 
reaction mix contained 10x RT-buffer (2 μl), 5.5 mmol/l MgCl2 (4.4 μl), 500 μmol/l 
of each deoxyNTP (4 μl), 2.5 μmol/l Random Hexamers (1 μl), 0.4 U/ μl        
RNase-inhibitor (0.4 μl), and 1.5 μl Rnase-free water. The solution was treated with 
0.01 U/ μl DNAase (0.2 μl) (Boehringer Mannheim, Mannheim, Germany) for 30 
min at +37ºC. The enzyme was inactivated by heat at +75ºC for 5 min and cooled to 
+20ºC. A Multiscribe Reverse Transcriptase enzyme (1.25 U/μl, 0.5 μl) was added. 
After 10 min incubation at +25ºC, the reverse transcription reaction was performed 
at +48ºC for 30 min. Inactivation at +95ºC for 5 min halted the reaction, and cDNA 
was stored at -20ºC. RT PCR was performed by use of an automated fluorometer, 
the ABI Prism 7700 Sequence Detection System (Applied Biosystems). The thermal 
cycling profile consisted of 3 stages: 2 min at +50ºC, 10 min at +95ºC, and 15 s at 
+95ºC, and 60 s at +60ºC; the amplification stage 3 was repeated for 50 cycles. 
 
FAM-labeled TaqMan gene expression assays were used to measure transcription 
levels of the selected genes (T-bet, cat.no. Hs00203436_m1, GATA-3 cat.no. 
Hs00231122_m1, IL-12r cat.no Hs00234651_m1, and IL-4r cat.no. 
Hs00166237_m1), and ribosomal 18S (cat no. Hs99999901_s1) was served as the 
endogenous control. PCR reactions were run in triplicate wells with 5 ng of template 
cDNA/well in a final volume of 25 μl, and expression of each cytokine was 
measured also from a calibrator cDNA, prepared from PHA (Sigma) -stimulated 
pooled peripheral blood mononuclear cells of healthy subjects. The comparative Ct 
method was used to quantitate the gene transcription in cord blood mononuclear 
cells. ΔCt (Ct of target gene – Ct of 18S) value of the calibrator was subtracted from 
the ΔCt (Ct of target gene – Ct of 18S) values of the analyzed cord blood samples, 
and the difference was determined as the ΔΔCt value. Results are expressed as 
relative units based on calculation of 2 –ΔΔCt, and give the relative amount of 
cytokine normalized to the endogenous control (18S) and compared to the calibrator 
(PE Applied Biosystems, ABI PRISM 7700 Sequence detection system, MA, USA). 
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4.3.7 Statistical analysis (I-IV) 
 
In Studies I and IV, the non-parametric Mann-Whitney U-test served for 
comparisons of all variables, since no variable was normally distributed, and the 
Wilcoxon signed-rank test was used to compare the cytokine levels in follow-up 
samples in Study I. Study II, the Wilcoxon signed-rank test was used to compare 
cytokines in follow-up (pre- and post-treatment) samples, and the Mann-Whitney  
U-test and Kruskall-Wallis tests were for cytokine comparisons of follow-up      
(pre- and post-treatment) samples, because of the great number of values under the 
detection limit and the non-normal distribution of data. Statistical tests were 2-tailed. 
In Studies II and III, all parametric comparisons were made after logarithmic 
transformation, because of skewed distributions, and analysis of variance (ANOVA) 
served for comparisons. Since differences existed in baseline values (pre-treatment 
values at visit 1, post-treatment values at visit 2) in Study II, these were taken as 
covariates in the analysis. The initial unit of measurement was produced by 
antilogarithm from baseline-adjusted geometric means. The data are presented with 
geometric means and 95% confidence intervals (CI). Logistic regression analysis 
was used for risk analyses in Study III. The correlations were analysed with        
non-parametric Spearman rank correlation. All statistical analyses were performed 
with SPSS for Windows (version 10.0), and the results were considered statistically 
significant when the p-value  was < 0.05. 
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5 RESULTS 
5.1 Immunological features associated with atopy and allergic diseases 
 
5.1.1 Cytokine secretion of PBMCs in CMA- and non-CMA infants (I) 
 
Cytokine secretion of PBMCs in response to OKT3/anti-CD28-stimulation in vitro 
was measured from cell culture supernatants of infants with eczema. Infants were 
under 12 months of age, and were suspected to have cow`s milk allergy (Flora1 
study). In Study I, OKT3/anti-CD28-stimulated IFN-γ secretion of PBMCs was 
significantly lower in infants with CMA than in non-CMA infants (median, 478 
pg/ml vs 857 pg/ml; p = 0.016). Decreased IFN-γ secretion occurred in infants with 
IgE-associated CMA. This decrease was significant in comparison with that of the         
non-CMA infants with an IgE-associated eczema (p = 0.001) (Fig 4). Secretion of 
IFN-γ was similar in infants with non-IgE-associated CMA and in non-CMA infants 
(median, 601 pg/ml vs 857 pg/ml). Infants with non-IgE-associated CMA had lower 
IL-4 and IL-5 secretion of PBMCs than did non-CMA infants without IgE 
association (p = 0.008 and p = 002, respectively), or non-CMA infants with         
IgE-association (p = 0.001 and p = 0.038, respectively), or infants with                
IgE-associated CMA (p = 0.002, and p = 0.004, respectively) (Fig 4). Secretion of 
IL-4 and IL-5 of PBMCs was similar in infants with IgE-associated CMA and in 
non-CMA infants (Fig 4).  Secretion of  IL-12 did not differ between CMA and non-
CMA infants (data not shown). 
 
5.1.2 Intracellular cytokines of CD4+ lymphocytes in CMA, and non-CMA 
infants, and in infants with IgE-, or non-IgE-associated eczema (I) 
 
Expression of the CD69 appeared in > 95% of OKT3/antiCD28-stimulated CD4+ 
lymphocytes, and in < 1% of unstimulated CD4+ lymphocytes. The numbers of CD4+ 
cells expressing IL-4, IL-5, or IFN-γ were similar in CMA and non-CMA infants (data 
not shown). Neither did the number of CD4+ cells expressing IL-4,    IL-5, or IFN-γ 
differ in infants with IgE-, or non-IgE-associated eczema (data not shown). 
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Figure 4. Secretion of IFN-γ, IL-4 and IL-5 by OKT3/antiCD28-stimulated PBMCs before 
treatment in infants with non-IgE-associated CMA (CMA, non-IgE), IgE-associated CMA (CMA, 
IgE), no CMA , no IgE association (No CMA, non-IgE), and no CMA with IgE-association (No 
CMA, IgE). Horizontal lines show median values. P values by Mann-Whitney U-test, ** p < 0.01,            
* p < 0.05. 
 
 
5.2 Immunological effects of probiotic bacteria 
 
5.2.1 Effects of probiotic bacteria on cytokine levels in vitro (I) 
 
In infants with CMA, OKT3/anti-CD28-stimulated IFN-γ secretion of PBMC 
increased significantly in the LGG group (p = 0.023), but no changes occurred in 
follow-up samples in the MIX (p = 0.239) or placebo groups (p = 0.086) (Wilcoxon        
signed-rank test). Individual changes (after-before) in  IFN-γ concentrations were 
calculated to validate the results (Mann-Whitney U-test). Secretions of IFN-γ 
increased in the LGG group more than in the placebo group (p = 0.006), but in the 
MIX group, the IFN-γ level increase was not significant in comparison with the 
placebo group (p = 0.058) (Fig 5). In infants with CMA, OKT-3-stimulated PBMCs 
secreted more IL-4 after treatment with MIX than after placebo (p = 0.034), and the 
change (after-before) in IL-4 secretion was significant in comparison with that of the 
placebo group (p = 0.028) (Fig 5). In the LGG and placebo groups, no differences 
were detectable between IL-4 secretion levels (Fig 4). OKT3/anti-CD28-stimulated 
IL-5 secretion of PBMC was similar in the LGG, MIX, and placebo groups (Table 
I). No changes during follow-up occurred in IL-12 secretion. IL-12 levels in all 
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samples were low (data not shown). Probiotic treatment had no effect on 
intracellular IL-4, IL-5, or IFN-γ activation in stimulated (OKT3 and CD28 
antibodies) CD4+ lymphocytes in CMA infants (data not shown). 
 
In infants with IgE-associated eczema, OKT3/anti-CD28-stimulated IFN-γ secretion 
of PBMC increased significantly in follow-up samples in the LGG group                
(p = 0.048), but no changes occurred in the MIX (p = 1.000) or placebo groups              
(p = 0.158) (Wilcoxon signed-rank test) (Table III, Fig 5). In comparison with the 
placebo, the level of IFN-γ secretion increased in the LGG group (p = 0.017), but no 
differences appeared in the MIX group in comparison with placebo (p = 0.319) 
(Table III). Probiotic treatment had no significant effect on IL-4-, IL-5- (Table III), 
or IL-12 (data not shown) secretion in infants with IgE-associated eczema, and had 
no effect on intracellular IL-4, L-5, or IFN-γ activation in stimulated (OKT3 and 
CD28 antibodies) CD4+ lymphocytes of infants with IgE-associated eczema (data 
not shown). 
 
Probiotic treatment had no effect on IL-4-, IL-5-, IL-12-, or IFN-γ secretion in 
stimulated (OKT3 and CD28 antibodies) PBMCs or on intracellular IL-4, IL-5, or 
IFN-γ in stimulated CD4+ lymphocytes in infants with non-IgE-associated eczema, 
or in non-CMA infants (data not shown). 
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Table III. OKT3- and anti-CD28-induced cytokine secretion of PBMCs before and after 
treatment. Shown as medians (ranges) (pg/ml). 
____________________________________________________________________ 
                                 IFN-γ                                           IL-5                             IL-4      
 
                  n    before               after                    n   before       after             n   before       after 
_______________________________________________________________________________ 
Eczemaa 
LGG         24  780(90-1780)   859(298-3501)    23  51(0-302)  79(0-281)  24  19(3-74)  19(7-46) 
MIX         21  492(23-2431)    663(59-1681)     18  69(0-289)  73(0-246)   21  18(4-53)  23(8-65) 
Placebo    17  955(231-3059)  765(316-2044)   16  57(0-211)  65(0-225)  17  23(7-51)  14(4-46) 
 
Eczema(IgE)b 
LGG         14  506(90-1006)    840(298-3501)* 13  91(0-302)  99(0-281)  14  22(3-74)  24(8-46) 
MIX         12  952(31-2431)    672(289-1658)    11  113(0-289)  82(0-246)12  19(4-53)  25(8-50) 
Placebo    12  1042(286-3059) 860(316-2044)   11 70(0-211)  66(0-225)   12  24(9-51)  24(11-46) 
 
CMA 
LGG        12  403(90-1780)    829(298-3501)*  11  51(0-302)  93(0-281)  12  19(9-74)  19(8-46) 
MIX        12  437(23-2431)     681(331-1681)     9  47(0-289)  83(0-245)  12  15(4-49)  22(13-65)* 
Placebo     9  836(286-1595)   579(316-1136)     8  56(0-138)  45(0-108)    9  21(7-32)  18(4-30)  
___________________________________________________________________ 
n =  number of samples 
a All infants with  eczema                                                                                                                                                                    
 bIgE-associated eczema  
Increase in comparison with placebo group *p < 0.05 
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Figure 5. Secretion of IL-4 and IFN-γ by OKT3/anti-CD28-stimulated PBMCs in LGG, MIX, and 
placebo groups in infants with CMA. First columns show distribution of pretreatment values, and 
second columns of posttreatment values, horizontal lines show medians. P-values by Mann-Whitney   
U- test.  
 
5.2.2 Effects of probiotic bacteria on plasma cytokine concentrations (II-III) 
 
5.2.2.1  Cytokines in allergy treatment study (Flora1) (II) 
 
The probiotic effect on plasma cytokine levels was analysed in infants with eczema 
and in those who were suspected to have cow`s milk allergy (Study II). In infants 
with IgE-associated eczema, IL-6 level increased in the LGG group (p = 0.023, 
Wilcoxon signed-rank test), but not in the MIX or placebo groups (Table IV). 
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Individual changes (after minus before) in plasma IL-6 concentrations were 
calculated to validate the results (Mann-Whitney U-test). The post-treatment plasma 
IL-6 level was higher in the LGG than in the placebo group (p = 0.036) (Table IV). 
Among all infants with eczema, changes in IL-6 levels in different treatment groups 
were non- significant (Table IV). 
 
In infants with eczema, the level of IL-10 in plasma in the MIX group increased 
significantly (p = 0.016, Wilcoxon signed-rank test), but the changes in IL-10 levels 
in LGG or placebo groups were non-significant. However, in infants with eczema, 
post-treatment plasma IL-10 levels were higher in LGG (p = 0.046) and MIX          
(p = 0.039) groups than in the placebo group (Table IV). In infants with                
IgE-associated eczema, no significant changes were detectable in plasma IL-10 
levels in follow-up samples (Table IV). Differing treatments had no effect on IL-4, 
IFN- γ, TGF-β1, or TGF-β2 levels in follow-up samples in infants with eczema, or 
in infants with IgE-associated eczema (data not shown). 
 
Table IV. Plasma IL-6 (pg/ml) and IL-10 (pg/ml) levels in all infants with eczema and 
with IgE-associated eczema treated with LGG, MIX, or placebo for 4 weeks. Shown as 
means (upper quartiles, ranges). 
_______________________________________________________________________ 
        IL-10                   IL-6 
                      n   Before                  After                          n   Before                    After 
Eczema 
LGG               47  1.6 (3.0, 0-7.9)   2.4  (4.4, 0-11.3)*      47  1.1 (0.0, 0-15.4)   2.4 (3.8, 0-20.3)  
MIX                38  1.3 (3.4, 0-4.9)   2.5  (3.8, 0-16.8)*      38  2.3 (3.9, 0-22.6)   2.6 (3.6, 0-35.8) 
Placebo           36  1.2 (3.0, 0.6.7)   1.5  (2.5, 0-19.0)*      36  0.7 (0.0, 0-7.4)     2.5 (0.0, 0-61.2) 
 
Eczema (IgE)a 
LGG               26  1.5 (3.0, 0-5.0)   2.3 (4.4, 0-11.3)         26  0.9 (0.0, 0-8.7)     3.4 (6.9, 0-20.3)** 
MIX               19  1.2 (3.3, 0-4.9)   2.1 (3.9, 0-5.5)           19  2.1 (3.9, 0-18.5)    2.0 (4.1, 0-17.0) 
Placebo          24  1.2 (3.2 0-6.7)    2.0 (3.4, 0-19.0)          24   1.0 (0.0, 0-7.4)    0.9 (0.0, 0-9.5)** 
______________________________________________________________________ 
a IgE-associated eczema 
* Mann-Whitney U-test: posttreatment LGG versus placebo, P = 0.046, MIX versus placebo, P = 0.039 
** Mann-Whitney U- test: posttreatment LGG versus placebo, P = 0.036 
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5.2.2.2 Cytokines in allergy prevention study (Flora2) (III) 
 
The probiotic effect on plasma cytokine levels at age 6 months was analysed in   
allergy-prone infants in the prevention study of allergic diseases. In addition, we 
studied the associations of cytokine levels at age 6 months with allergic diseases and            
IgE-sensitisation at age 2 years (Study III). Plasma IL-10 levels were higher in the 
probiotic than in the placebo group in the whole study population (p = 0.002)   
(Table V). Moreover, children with eczema or IgE-sensitization at age 2 years 
showed significantly higher IL-10 concentrations at age 6 months in the probiotic 
group than in the placebo group (p = 0.001 and p = 0.007) (Table V). No such 
difference emerged for the non-allergic group (Table V). In the whole study 
population, plasma IL-10 levels at age 6 months did not associate with the eczema at 
age 2 years (OR 1.00; 95% CI 0.44 to 2.30; p = 1.000), nor with the                      
IgE-sensitization (OR 1.43; 95% CI 0.60 to 3.40; p = 0.417). Neither did plasma    
IL-10 values at age 6 months in the placebo group associate  with eczema (RR 0.67; 
95% CI 0.31 to 1.45; p = 0.289), or with IgE-sensitization (RR 0.67; 95% CI 0.27 to 
1.64; p = 0.350) at age 2 years. Plasma IL-2, IL-4, IL-6, IFN-γ, and TNF-α values 
were low, most of the values below  detection limits (data not shown).   
 
Table V. Plasma IL-10 (pg/ml) levels in all children, in children with eczema, in       
IgE-sensitized children, and in non-allergic, non-sensitized children treated with 
probiotic bacteria or placebo for 6 months. Shown as geometric means (ranges). 
____________________________________________________________________ 
            Probiotic                      Placebo 
                          n                                         n                                   P value 
 
All children 45/52   4.46  (1.4-53.3) 26/46   2.85  (1.4-8.8)     0.002                 
Eczema   14/16   5.08  (1.4-13.3)         8/18   2.39  (1.4-5.8)     0.001                 
IgE-sensitized children  16/18   5.16  (1.4-14.6)         6/12   2.61  (1.4-8.0)     0.007         
Non-allergic,   18/24   4.05  (1.4-53.3)       14/22   3.20  (1.4-8.8)     0.307        
non-sensitized children 
_______________________________________________________________________________
n represents number of samples above detection limit / total number of samples  
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5.2.3 Effects of probiotic bacteria on plasma CRP levels (II-III) 
 
5.2.3.1  CRP in allergy treatment study (Flora1) (II) 
 
The probiotic effect on plasma CRP levels was analysed in infants with eczema and 
in those who were suspected to have cow`s milk allergy (Study II).         
Pretreatment-adjusted post-treatment serum CRP levels were significantly greater in 
the LGG than in the placebo group in infants with IgE-associated eczema (Table VI 
and Fig 6). In the MIX group, the difference in CRP levels in comparison with the 
placebo group was non-significant (Fig 6). Pretreatment-adjusted CRP levels did not 
differ between infants with IgE-mediated CMA and infants in the whole study 
population (infants with eczema) after probiotic or placebo treatment (Table VI).   
 
5.2.3.2 CRP in allergy prevention study (Flora2) (III) 
 
The probiotic effect on plasma CRP levels at age 6 months was analysed in    
allergy-prone infants in the prevention study of allergic diseases. In addition, we 
studied the association of CRP level at age 6 months with allergic diseases and IgE-
sensitisation at age 2 years (Study III). Plasma CRP levels were significantly higher 
in the probiotic than in the placebo group in the whole study population (p = 0.008) 
(Table VII). Furthermore, children with eczema at age 2 years showed significantly 
higher plasma CRP levels in the probiotic than in the placebo group (p = 0.008) 
(Table VII). When compared, values of infants who at age 2 years were non-allergic 
or were IgE-sensitized, showed no differences between those in the active or placebo 
group (Table VII). Increased plasma CRP level at age 6 months reduced risk for 
eczema at age 2 (OR 0.4; 95% CI 0.17 to 0.94; p = 0.034). The association with                 
IgE-sensitization was not significant (p = 0.710). 
 
In the placebo group, high plasma CRP values reduced risk for eczema at age 2 
years (RR 0.41; 95% CI 0.16 to 1.05; p = 0.038), but the association with            
IgE-sensitization was non-significant (p = 0.473). 
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Figure 6. Pretreatment (first columns of pairs) and post-treatment (second columns) plasma CRP 
geometric means and 95% CIs in LGG, MIX, and placebo groups in infants with IgE-associated 
eczema. Post-treatment plasma CRP adjusted by pre-treatment value, P value by Fisher`s test,       
* P = 0.021 
 
 
5.2.4 Effects of probiotic bacteria on adhesion molecules (II) 
 
 
Probiotic effects on serum  sE-selectin and sICAM-1 levels were analysed in infants 
with eczema and in those who were suspected to have cow`s milk allergy (Study II). 
Pretreatment-adjusted post-treatment serum sE-selectin levels were higher in the 
LGG and MIX groups than in the placebo group in infants with IgE-mediated CMA 
(Table VI). In the whole study population (infants with eczema), and in infants with 
IgE-associated eczema, no differences were detectable between treatment groups 
(Table VI). Pretreatment-adjusted post-treatment serum sICAM-1 did not differ 
significantly between treatment groups or in any subgroup analyses (data not 
shown). 
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Table VI. Comparison of plasma levels of CRP (ug/ml) and sE-selectin (ng/ml) in all 
infants with eczema, IgE-associated eczema, or IgE-mediated CMA treated with LGG, 
MIX, or placebo for 4 weeks. Shown as geometric means, 95% CI. 
____________________________________________________________________ 
 
   n     CRP (μg/ml)          P value        n     sE-selectin          P value 
                                                                   ANCOVA                                       ANCOVA 
____________________________________________________________________ 
Eczema 
LGG 52   0.63 (0.48-0.84)   52  86.3 (79.8-93.1) 
MIX 42   0.67 (0.49-0.91)   41  88.9 (81.5-96.8) 
Placebo 38   0.43 (0.31-0.60)   36  86.5 (78.7-94.8) 
 0.130              0.865 
Eczema (IgE)a 
LGG 31   0.83 (0.56-0.81)*    31  92.9 (84.3-102.3) 
MIX 21   0.79 (0.49-1.27)   20  101.2 (89.7-114.0) 
Placebo 26   0.42 (0.27-0.65)*   24  88.9 (79.6-99.3) 
             0.047              0.288 
CMA (IgE)b 
LGG 16   0.88 (0.46-1.68)   16  86.7 (75.2-100.0)* 
MIX   8   1.32 (0.52-3.36)     8  91.6 (74.8-111.9)* 
Placebo   8   0.46 (0.18-0.85)     8  64.9 (53.0-79.3)* 
             0.293              0.035 
____________________________________________________________________ 
ANCOVA, Analysis of covariance, post-treatment values adjusted by pretreatment values. 
a IgE-associated eczema 
 bIgE-mediated cow’s milk allergy 
* Fisher least-significant-difference test: LGG, or MIX versus placebo,  P < 0.05 
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Table VII. Plasma CRP (mg/l) levels in all children, in children with eczema, in       
IgE-sensitized children, and in non-allergic, non-sensitized children treated with 
probiotic bacteria or placebo for 6 months. Shown as geometric means (ranges). 
____________________________________________________________________ 
                            Probiotic                            Placebo 
                                          n                                             n                                      p value 
 
All children 52/52   0.19  (0.02-2.48)   46/46   0.10  (0.01-2.08)     0.008                 
Eczema 16/16   0.18  (0.03-1.51)         18/18   0.06  (0.01-0.28)     0.008         
IgE-sensitized children 18/18   0.19  (0.03-1.51)         12/12   0.11  (0.04-0.65)     0.207                 
Non-allergic, 24/24   0.21  (0.02-2.48)         22/22   0.14  (0.02-2.08)     0.138        
non-sensitized children 
_______________________________________________________________________________
n represents number of samples above detection limit / total number of samples  
                  
 
5.2.5 Effects of probiotic bacteria on IgE, IgA, and specific antibody levels (III) 
 
Probiotic effects on plasma IgE, IgA, and specific antibody levels at age 6 months 
were analysed in allergy-prone infants in the prevention study of allergic diseases. In 
addition, we studied the associations of IgE and IgA levels at age 6 months with 
allergic diseases and IgE-sensitization at age 2 years (Study III). Total IgE  levels in 
plasma at age 6 months were higher in the probiotic than in the placebo group in the 
whole study population (p = 0.047), and in non-allergic, non-sensitized children     
(p = 0.042) (Table VIII). No differences in total IgE  levels were detectable between 
treatment groups in children with eczema (p= 0.544), or with IgE-sensitization at 
age 2 years (p = 0.646) (Table VIII). High plasma total IgE  values at age 6 months 
led to increased risk for IgE-sensitization at age 2 years (OR 3.48; 95% CI 1.34 to 
9.03; p = 0.008), and high total IgE  values tended to lead to risk for eczema (OR 
2.19; 95% CI 0.92 to 5.20; p = 0.074). Probiotic bacteria had no effect on CM-, or 
egg white-IgE antibody levels (data not shown). Most of the specific IgE levels fell 
below detection limits (data not shown). 
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Total IgA levels in plasma at age 6 months were higher in the probiotic than in the 
placebo group in the whole study population (p = 0.016) (Table VIII), and in         
non-allergic, non-sensitized children (p = 0.050) (Table VIII). Total IgA levels did 
not differ between treatment groups in children with eczema (p = 0.302), or with       
IgE-sensitization at age 2 years (p = 0.516) (Table VIII). High plasma total IgA level 
at age 6 months elevated risk for eczema at age 2 years (OR 3.40; 95% CI 1.39 to 
8.37; p = 0.006). No association with risk for IgE-sensitization and total IgA levels 
at age 6 months was detectable (OR 1.23; 95% CI 0.51 to 2.97;  p = 0.652). 
Probiotic bacteria had no effect on CM-, OVA-, or casein- IgA, or IgG levels (data 
not shown). 
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5.3 Immunological disturbances of CBMCs associated with atopy and allergic 
diseases (IV) 
 
5.3.1 Transcription factors GATA-3 and T-bet, and IL-4- and IL-12 receptors 
in CBMCs (IV) 
 
CBMCs from neonates at high genetic risk for allergy were stimulated with        
beta-lactoglobulin (β-LG) and phytohaemagglutinin (PHA), followed by analysis of 
T-cell polarization-associated IL-4 receptor and IL-12R expression and the 
respective transcription factors GATA-3 and T-bet. The responses were compared 
with allergic phenotype at age 2 years. GATA-3 expression was higher in                  
PHA-stimulated CBMCs in children with IgE-sensitization at age 2 than in the    
non-sensitized, non-allergic children (p = 0.03), and tended to be higher also in 
children with IgE-associated disease than in non-sensitized, non-allergic children   
(p = 0.05) (Table IX).  No differences in GATA-3 expression levels appeared in the 
group of children with any allergic disease in comparison with the non-sensitized,             
non-allergic children (Table IX). PHA-induced GATA-3 expression correlated 
positively with PHA-stimulated secretion of IL-5 (p = 0.003, r = 0.300) and IL-13  
(p =  0.007, r = 0.278) in cord blood mononuclear cells. The expression levels of    
T-bet, IL-4R, or IL-12R in PHA-stimulated CBMC did not differ between the 
groups (Table IX). Maternal probiotic supplementation had no effect on 
transcription factor GATA-3, on T-bet, on IL-12R, or on IL-4R expression of 
CBMC (data not shown). 
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Table IX. Expression levels of transcription factors GATA-3 and T-bet, and IL4-R, and IL12-R in 
PHA-stimulated cord blood mononuclear cells (CBMCs). Results are presented as 1000 x relative 
units based on calculation of 2 –ΔΔCt (PHA stimulation –no stimulation). Shown as medians 
(ranges). 
 
 
 
 
 
 
 
 
n, number of samples 
p < in comparison with non-sensitized, non-allergic children 
 
 
5.3.2 Cytokine secretion by CBMCs (IV) 
 
CBMCs from neonates at high genetic risk for allergy were stimuled with               
β-lactoglobulin (β-LG) and PHA, and then IL-2, IL-4, IL-5, IL-10, IL-13 and IFN-γ 
secretion of CBMCs were analysed. The responses were compared with those of the 
allergic phenotype at age 2 years. The IL-5 response of β-LG-stimulated CBMCs 
was higher in children with IgE-sensitization at age 2 than in the non-sensitized, 
non-allergic children (p = 0.013) (Table X). No differences in IL-5 responses of     
β-LG-stimulated CBMCs appeared in children with any allergic disease in 
comparison with the non-sensitized, non-allergic children (Table X). The IL-5 
response of PHA-stimulated CBMC tended to be higher in IgE-sensitized children 
than in non-sensitized, non-allergic children (p = 0.073) (Table XI). No significant 
differences in IL-5 responses of PHA-stimulated CBMCs appeared in children with 
Allergic disease IgE-associated 
disease
IgE-sensitization Non-sensitized, 
non-allergic 
children
n n n n
GATA-3 38 166 (-302-809) 17 247 (-302-809)* 29 233 (-353-809)* 39 120 (-187-354)
T-bet 39 13 (-395-164) 17 13 (-395-48) 30 11 (-395-287.9) 39 15 (-149-106)
IL-12r 39 266 (-1634-905) 17 232 (-1634-905) 30 232 (-1634-905) 39 232 (-1483-1087)
IL-4r 39 226 (-306-455) 17 254 (-306-455) 30 227 (-306-736) 39 201 (-7339-1335)
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any allergic disease in comparison with the non-sensitized, non-allergic children 
(Table XI). Neither IFN-γ secretion of PHA- , or β-LG-stimulated CBMCs differed 
between groups (Tables X and XI). The IL-2 response of PHA-stimulated CBMCs 
was higher in children with IgE-sensitization at age 2 than in the non-sensitized, 
non-allergic children (p = 0.026) (Table XI), whereas no difference emerged 
between children with any allergic disease when compared with non-sensitized,   
non-allergic children (Table XI). IL-4, IL-10, and IL-13 secretion of PHA- (Table 
XI), or β-LG-stimulated CBMCs did not differ between the groups (data not shown). 
Maternal probiotic supplementation had no effect on IL-2, IL-4, IL-5, IL-10, IL-13, 
or IFN-γ secretion of CBMCs (data not shown). 
 
Table X. IFN-γ and IL-5 secretion by β-lactoglobulin (β-LG) -stimulated  
cord blood mononuclear cells. Shown as medians (ranges) pg/ml. 
____________________________________________________________________ 
                            IFN-γ                              IL-5 
                          β-LG                                β-LG 
                                          n                                             n                                    
Allergic disease    11/40   0  (0-5767.7)      19/40   0  (0-132.2)                     
IgE-associated disease      7/19   0  (0-5767.7)                 6/19   0  (0-132.2)      
IgE-sensitization    14/32   0  (0-5767.7)               13/32   0  (0-312.9)*      
Non-allergic,    17/39   0  (0-3670.1)                 6/39   0  (0-248.8)      
non-sensitized children 
_______________________________________________________________________________ 
n, number of samples above detection limit / total number of samples 
* p < 0.05 in comparison with non-sensitized, non-allergic children  
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6 DISCUSSION 
6.1 Development of allergic diseases and IgE-sensitization in infancy - 
    an immunologic perspective 
 
Allergic diseases in infancy have traditionally been considered to be Th2-type 
diseases resulting from an imbalance in Th1/Th2 deviation from the neonatal Th2 
responsiveness instead of Th1 type responses (Holt et al. 1997; Prescott et al. 1999; 
van der Velden et al. 2001). In IgE-mediated allergy, Th2-type cytokines: IL-4,    
IL-5, and IL-13 mediate allergic inflammation. IL-4 and IL-13 regulate IgE-class 
switching, whereas IL-5 is necessary for the activation, recruitment, and 
differentiation of eosinophils (Abbas et al. 1996; Romagnani 1998). The rigid 
Th1/Th2 paradigm, however, fails to explain the immunopathology in all types of 
allergic responses, while infants developing allergic disease appear not to follow a 
strict Th1/Th2 dichotomy. Interestingly, the Th1/Th2 division has been revised 
recently, because of the discovery of another functional Th subset, Th17 (Steinman 
2007). Its role in allergic diseases is still undetermined. In Study I, the cytokine 
secretion after OKT3/anti-CD28 stimulation of PBMCs was different in infants with 
IgE-, or non-IgE associated cow´s milk allergy. In non-IgE-associated disease,    
Th2-type cytokine (IL-4 and IL-5) secretion by stimulated PBMCs was significantly 
lower than in non-allergic infants, or in infants with IgE-association. By contrast, 
infants suffering IgE-associated cow’s-milk allergy had a low IFN-γ response from 
their stimulated PBMCs. These results support observations that PBMCs of subjects 
with atopic disease have reduced IFN-γ secretion capacity (Jung et al. 1995; Prescott 
et al. 1999). The results are also in good agreement with a classification of food 
hypersensitivities into IgE- or non-IgE-mediated immune disorders (Kay 2001; 
Sabra et al. 2003; Sampson 2004). The non-IgE-mediated CMA appears to 
demonstrate different signalling mechanims from those of IgE-mediated CMA. In 
fact, mixed forms of IgE/non-IgE mechanisms of food allergies also exist (Sabra et 
al. 2003), which may partly explain the variation in cytokine secretion of stimulated 
PBMCs between allergic infants in Study I.   
 
Studies have demonstrated that aberrant CBMC responses are associated with an 
atopic phenotype during early infancy. Several in vitro studies showed a reduced 
number of Th1-type, IFN-γ-producing cells (Nilsson et al. 2004), reduced IFN-γ 
secretion of CBMCs, and a greater Th2-biased allergen responsiveness in infants 
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with allergic disease or sensitization during the first years of life (Tang et al. 1994; 
Warner et al. 1994; Liao et al. 1996; Kondo et al. 1998; Macaubas et al. 2003; 
Neaville et al. 2003). In some studies, lower levels of both Th1 and Th2 type 
cytokines, including IFN-γ, IL-4, IL-6, IL-10, and IL-13, were detectable in infants 
developing atopic disease than in healthy infants (Prescott and Holt 1998; Prescott et 
al. 1999). Studies of IL-13 secretion in CBMCs have given conflicting results: In 
some studies, enhanced IL-13 levels at birth were associated with the subsequent 
development of atopic symptoms (Spinozzi et al. 2001; Ohshima et al. 2002; Lange 
et al. 2003), but in contrast babies at risk for atopic disease in infancy were reported 
to display defective IL-13 production at birth, speculated to represent an inherent 
immaturity in the development of T cell-cytokine responses in infants with an atopic 
genotype (Williams et al. 2000). Pronounced production of IL-4 and IL-5 in CBMCs 
was associated with the subsequent development of atopy (Piccinni et al. 1996; 
Sharp et al. 2003); an elevated frequency of IL-4-producing CBMCs and IL-4/IFN-γ 
ratio in response to PHA-stimulation in CBMC was also observable in newborns at 
high risk for atopy (Gabrielsson et al. 2001). 
 
We found (IV) that IgE-sensitized infants at age 2 years exhibited pronounced Th2 
skewing of CBMCs responses as assessed by higher GATA-3 expression and IL-5 
secretion of stimulated CBMCs than did non-sensitized, non-allergic infants. 
However, CBMC responses did not differ between infants with allergic disease and 
non-sensitized, non-allergic infants at age 2. The transcription factor GATA-3 seems 
to play a vital role in the induction of Th-2 cytokine gene expression, as it activates 
and stabilizes the expression of IL-4, IL-5, nd IL-13 in T-cells, possibly in            
co-operation with other activation factors (Zhang et al. 1997; Zheng and Flavell 
1997; Zhang et al. 1998; Lavenu-Bombled et al. 2002). Interestingly, ectopic 
expression of GATA-3 was sufficient to drive IL-5, but not  IL-4 gene expression, 
expression of which possibly needs multiple inducing factors (Ranganath et al. 
1998; Zhang et al. 1998). In Study IV, no defect in IL-4 secretion or in IL-4 receptor 
expression of stimulated CBMCs was detectable, which is in agreement with the 
GATA-3-driven expression studies; multiple factors seem to affect the induction of 
IL-4. Neither did IL-10, IL-13, or Th1-type markers, the transcription factor T-bet, 
IL-12 receptor expression, or secreted IFN-γ of stimulated CBMCs differ between 
the IgE-sensitized, non-IgE-sensitized, allergic or non-allergic children at age 2. 
Based on our results, the priming of GATA-3 and the IL-5 pathway can occur in 
utero, and the primary feature in T-cells predisposing to IgE-sensitization directly 
favours Th2 deviation. Interestingly, eosinophils may play a primary role in IgE-
sensitization, because IL-5 promotes eosinophilic inflammation by regulating the 
proliferation, differentiation, and activation of eosinophils (Abbas et al. 1996; 
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Romagnani 1997; Miescher and Vogel 2002). Our results are in accordance with the 
hypothesis that processes predisposing to allergic disease begin early, possibly 
already in utero (Prescott et al. 1998a).  
 
6.2 Probiotic bacteria and immune regulation  
 
The interactions between enteric flora and the innate and adaptive immunity, which 
control the immune homeostasis of the gut (Guarner 2006), provide the rationale for 
the use of probiotic bacteria as immunomodulatory agents. In the developed world, 
the prevalence of allergic diseases and IgE-sensitization continues to increase (von 
Mutius 1998; Asher et al. 2006). The “hygiene hypothesis” was introduced as an 
explanation for this increase in atopic diseases, an idea based on observations of an 
inverse correlation between family size and allergic rhinitis. Infections acquired 
from older siblings were suggested to confer protection from the development of an 
atopic phenotype (Strachan 1989). Recently, an alternative interpretation of the data 
supporting the hygiene hypothesis was designated the “microflora hypothesis”. This 
hypothesis proposes that the increase in the incidence of allergic airway disease is a 
consequence of perturbations in the gastrointestinal microbiota because of antibiotic 
and dietary changes in industrialized countries. These perturpations are proposed to 
have disrupted the normal microbiota-mediated mechanisms of immunological 
tolerance in the mucosa (Noverr and Huffnagle 2005). This altered-flora hypothesis 
could also partly explain the increase in incidence of allergies and IgE-sensitization 
during early infancy in developed countries. Experimental studies in mice support 
this view, by demonstrating the essential role of intestinal colonisation in 
achievement of oral tolerance (Sudo et al. 1997; Maeda et al. 2001). Probiotic 
bacteria are candidate agents for prevention and treatment of allergic diseases by 
providing beneficial immunoregulatory signals (I-III).  
 
At birth, the gastrointestinal tract is sterile, but upon delivery, colonisation begins. 
Environmental factors such as colonisation with microbes, infections, and other 
antigen contacts early in life have a great impact on development of allergic 
symptoms, some factors possibly predisposing to and some preventing the outcome 
of the allergic phenotype. Several studies indicate that the composition of the gut 
flora differs among the atopic vs. non-atopic and in industrialized vs. developing 
countries (Adlerberth et al. 1991; Björksten et al. 1999; Böttcher et al. 2000; 
Björksten et al. 2001; Kalliomäki et al. 2001a; Kirjavainen et al. 2001, 2002; 
Penders et al. 2006). Pregnancy and early infancy may be critical periods for 
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preventing the onset of allergic disease and IgE-sensitization. Therefore probiotic 
supplementation for high-risk infants is an attractive possibility for an 
immunomodulatory approach in early allergic diseases. In Study IV, bacterial 
supplementation during the last month of pregnancy, however, did not alter the 
infants’ immune responses. It seems likely that probiotic supplementation affects the 
immune system of the infant after delivery when direct contact with intestinal cells 
and colonization takes place. 
 
In Study III, we showed that probiotics, when given to infants at high risk for 
allergic diseases, induced an inflammation, detected as increased plasma CRP 
levels. At age 6 months, this was associated with decreased risk for eczema at age 2 
years, but the CRP-associated decrease in risk for eczema was not restricted to 
probiotic use, as the association was seen also in infants who received the placebo 
product. Thus, low-grade inflammation may control the tolerance achievement and 
generate protection from eczema. Interestingly, Lactobacillus GG supplementation 
for 4 weeks to infants suffering IgE-associated eczema induced an increase in serum 
CRP levels (II), with greater reduction in clinical symptoms (Viljanen et al. 2005b), 
when compared to the placebo group. A tendency toward higher CRP values 
appeared also in infants with IgE-associated eczema who received a mixture of 
probiotics (II). Probiotic supplementation, however, had no effect on CRP levels in 
some infants with eczema or in infants with CMA (II). The confounding factor may 
be inflammation induced by the disease itself, although no significant differences in 
baseline SCORAD values were detectable between treatment groups. 
 
Adhesion molecules such as sE-selectin and ICAM-1 levels in plasma were analysed 
among infants with eczema and suspected cow´s milk allergy (II). As expressed on 
endothelial cells, and after activation of inflammatory mediators, they mediate the 
lymphocyte homing processes (Bevilacqua and Nelson 1993; Kansas 1996). 
Interestingly, plasma levels of sE-selectin increased and were significantly higher 
after probiotic treatment than in the placebo group in infants with IgE-mediated 
cow´s milk allergy. ICAM-1 levels were unaffected. These results support the view 
that probiotic bacteria induce a low-grade inflammation which aids the selective 
recruitment of lymphocytes; sE-selectin, but not ICAM-1 has been observed to 
correlate positively with the activity of atopic eczema (Yamashita et al. 1997; 
Wolkerstorfer et al. 1998). In contrast, we demonstrated a greater reduction in 
clinical symptoms in infants with IgE-associated eczema in the probiotic group than 
in the placebo group, but detected higher sE-selectin levels in infants with IgE-
mediated CMA in the probiotic group than in the placebo group. Potentially after 
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this kind of immunological phenomenon of increased homing, a clinical benefit is 
also seen in food allergic infants who react to ingested antigens. 
 
The immune response induced by probiotics seems to be modulated by the host and 
is strain specific. According to clinical observations (Abrahamsson et al. 2007; 
Kukkonen et al. 2007; Rosenfeldt et al. 2003; Weston et al. 2005; Viljanen et al. 
2005b) and to the immunological responses detected in the present study, children 
especially with IgE-associated disease (I-II) or with a primary defect favouring   
IgE-reactivity (III) seem to benefit from probiotic supplementation. Interestingly, 
the beneficial effect of probiotic bacteria was absent from infants with                 
non-IgE-associated eczema (Rosenfeldt et al. 2003; Viljanen et al. 2005b; 
Abrahamsson et al. 2007). In the present study (I-III), the immunological effects of 
different bacterial strains were not, however, evaluated separately, exept for 
Lactobacillus GG, this is an obvious limitation to the study. Our results suggest that 
strains seem to stimulate immune cells differently, possibly also having antagonistic 
effects. A 4-week Lactobacillus GG supplementation concomitantly enhanced 
plasma IL-6 and CRP levels in infants with IgE-associated eczema, but plasma IL-6 
levels between the probiotic mixture and placebo groups did not differ (II). These 
differing stimulation patterns might explain the lower plasma IL-6 levels detected in 
infants who received the probiotic mixture with the same amount of Lactobacillus 
GG bacteria than in those receiving solely Lactobacillus GG supplementation (II). 
Lactobacillus GG seems to activate the innate immune system, observed as 
increased plasma CRP and IL-6 levels. The activation of the innate immune system 
via TLRs, possibly functioning also after Lactobacillus GG ingestion, is suggested 
as providing an important link between microbes, normal immune development, and 
an atopic phenotype (Braun-Fahrlander et al. 2002; Abreu et al. 2005). 
 
Intriguingly, plasma levels of IL-10 were higher in the probiotic mixture group than in 
the placebo group both in infants with eczema (II) and in the preventive study in 
atopy-prone infants after 6 months of probiotic supplementation (III). Lactobacillus 
GG alone did not raise plasma IL-10 levels, although higher posttreatment IL-10 
levels appeared in the Lactobacillus GG group than in the placebo group (II). During 
the probiotic treatment of infants with eczema and suspected cow´s milk allergy, we 
demonstrated no significant changes in the plasma levels of IL-4 (II), which is a 
fundamental cytokine in allergic immune responses, inducing B-cell switching to IgE 
production and being a key initiator of IgE-dependent mast-cell-mediated reactions 
(Galli 1993). Neither were TGF-β1 nor TGF-β2 plasma levels affected by probiotics in 
these infants (II). Increased IL-10 and TGF-β levels have been associated with 
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induction of oral tolerance (Zemann et al. 2003). Even though we showed no changes 
in TGF-β levels, the possibility that TGF-β levels are affected by probiotics cannot be 
excluded. We measured the peripheral blood plasma levels of these cytokines. 
Possibly the increased TGF-β levels after probiotic supplementation would be detected 
at the mucosal sites instead of in the peripheral blood.  
 
In Study III, plasma total IgA levels in plasma at age 6 months were higher in the 
probiotic than in the placebo group. Similar results are apparent in vaccination 
studies (Isolauri et al. 1995; Fang et al. 2000). High plasma total IgA level at age 6 
months led to increased risk for eczema at age 2; this could serve as a compensatory 
mechanism of an injured immune system, such as a result of the increase in gut 
permeability observed in children with atopic dermatitis (Rosenfeldt et al. 2004). 
Specific (CM-, α-casein-, and OVA) IgA and IgG levels remained unaffected by 
probiotics. Unexpectedly, total IgE  levels in plasma at age 6 months were higher in 
the probiotic than in the placebo group, but food-antigen-specific IgE concentrations 
did not differ between the groups. A probiotic-induced increase in total IgE  was 
observable in non-allergic, non-sensitized children, but not in allergic children (III), 
which is reasonable, because increased IgE levels are closely associated with 
allergic reactions. In fact, we found that high plasma total IgE  values at age 6 
months led to increased risk for IgE-sensitization at age 2 years and tended also to 
increase risk for eczema. The probiotic-induced response in infants was 
characterized by increased plasma IL-10, total IgE, and CRP levels, without 
induction of an allergen-specific IgE response (III).  
 
Similar changes are, surprisingly, seen in helminth infections; helminth infections 
and atopic diseases are associated with similar immunological phenomena, such as a 
Th2-skewed cytokine response and high levels of IgE and eosinophilia. Helminths 
stimulate Th2-type reactions, but protect from atopic diseases (Yazdanbakhsh et al. 
2002; Maizels 2005). A low prevalence of atopic diseases has been reported in 
populations where helminth infections are common (Lynch et al. 1987; van den 
Biggelaar et al. 2000; Vartiainen et al. 2002; Voor et al. 2005). The 
immunomodulatory effect of probiotic bacteria in infants might be a paradoxical 
stimulation of Th2-type response. It has been suggested that the probiotic bacteria 
generate a beneficial anti-inflammatory response (Majamaa and Isolauri 1997; Pessi 
et al. 2000; Kalliomäki et al. 2001b), but according to our findings, the probiotics 
instead modulate immune responses by inducing a low-grade inflammation, 
response resembling helminth-like infections.  
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6.3 Methodological considerations 
 
In Study III, most of the plasma IL-2, IL-4, IL-6, IFN-γ, and TNF-α levels were 
below detection limits, and in Study II, plasma IL-2 values were below their 
detection limit and IFN-γ values very low. In these studies we thus could not 
evaluate the role of probiotic supplementation for the levels of these cytokines in 
plasma, which does not exclude the possibility that in children they are affected by 
probiotic supplementation. In addition, their being local mediators, only major 
changes may reflect changes in plasma. In Study I, IL-12 levels remained low or 
were below their detection limit after in vitro stimulation of PBMCs with CD3 and 
CD28 antibodies. This finding is not unexpected, because IL-12 is secreted by 
monocytes, and the stimulation used acts mainly by activating T-cells. We cannot 
exclude the role of probiotics regarding monocytes. It would be reasonable to 
believe that interaction of monocytes and dendritic cells with probiotics via TLRs 
stimulates immune responses mediated by cytokines. According to the literature, 
TLR ligand exposures may provide an important link between microbes, normal 
immune development, and the atopic phenotype (Braun-Fahrlander et al. 2002; 
Abreu et al. 2005).  
 
In Study I, intracellular cytokine expression (IL-4, IL-5, and IFN- γ) of lymphocytes 
were similar between infants showing differing clinical outcomes. Neither did 
probiotic treatment have an effect on intracellular cytokine activation in 
lymphocytes stimulated with CD3 and CD28 antibodies. Our method used for 
detecting intracellular cytokines produced high intra-assay and inter-assay variation, 
which may explain why no differences were evident between these groups. It is also 
possible that detection of cytokine-expressing cells does not necessarily correlate 
with the amount of protein secreted.  
 
In Studies I and II, we performed a cow´s milk challenge after the treatment. 
Probably the immunological effects of probiotic bacteria after the challenge would 
have been weaker than before the treatment, and therefore might have given an 
erroneous negative result regarding the effect of treatment. In addition, according to 
ethical guidelines, it was obligatory to eliminate the suspected allergen and start a 
proper elimination diet and skin treatment. 
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In Study IV we compared the stimulation responses of CBMCs between infants all 
of whom were predisposed to atopy, with at least one of their parents having a               
doctor-diagnosed allergic disease. No control group without genetic risk for atopy 
was analysed, an obvious limitation of this study.  
 
6.4 Ethical considerations 
 
The ethics committee of the Hospital for Children and Adolescents, University of 
Helsinki, found the Flora1 and Flora2 study protocols ethically acceptable. The 
probiotic strains used in the study have well-documented safety properties. Previous 
studies of probiotic supplementation have shown their positive clinical effects on the 
prevention and treatment of atopic diseases (Majamaa and Isolauri 1997; Isolauri et 
al. 2000; Kalliomäki et al. 2001b, 2003; Rosenfeldt et al. 2003; Viljanen et al. 
2005b; Abrahamsson et al. 2007). Based on these findings, we assumed that infants 
would benefit from probiotic treatment.  
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7 CONCLUSIONS 
Interest is growing in developing therapeutic applications and primary prevention 
strategies for allergic diseases, and finding ways to select high-risk infants for 
prevention programs. Essential to this approach is a clear understanding of the 
immunological processes in early life which promote IgE-sensitization and lead to 
allergic disease. Thus far, no such marker predicting atopy or aiding in preventing 
the disease at an individual level has emerged. Immunological measurements in this 
context are largely experimental, with no current diagnostic application. Research 
has, however, considerably enhanced understanding of immune responses during 
early infancy and clarified the mechanisms of allergic diseases and IgE-
sensitization. Probiotic bacteria are an attractive possibility for an 
immunomodulatory approach in early allergic diseases, but the immunological 
effects of probiotic bacteria are poorly known. Our results show an association 
between CBMC immune responses and IgE-sensitization at age 2, and highlight the 
immunological effects of probiotic bacteria in infants with allergic diseases and in 
infants at genetic risk for allergies. The main conclusions of the study are: 
 
1. Priming of GATA-3 and the IL-5 pathway may occur in utero. Higher GATA-3 
expression and IL-2 and IL-5 secretion of stimulated CBMCs were detected in    
IgE-sensitized infants at age 2 than in non-allergic, non-sensitized infants. A 
primary feature in T-cells predisposing to IgE-sensitization seems to directly favour 
Th2 deviation.  
 
2. Immunological effects of probiotic bacteria are modulated by the host. Differing 
immunological responses were apparent in the infants with differing clinical 
outcomes. The probiotic mixture raised plasma IL-10 levels, while IL-6 levels 
increased after Lactobacillus GG treatment, suggesting that the immune response 
induced by probiotics is strain-specific. 
 
3. Low-grade inflammation may control tolerance achievement and generate protection 
from eczema. In infants with IgE-associated eczema, Lactobacillus GG treatment 
induced an increase in plasma CRP and IL-6 levels. The probiotic mixture, when given 
to infants at high risk for allergic diseases, raised plasma CRP levels. A higher CRP level 
at age 6 months was associated with decreased risk for eczema at age 2. A CRP-
associated decrease in risk for eczema was not restricted to probiotic use. 
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4. The beneficial immunomodulatory effects of probiotic bacteria in infants 
resemble immune profiles that are characteristic for chronic low-grade 
inflammation, a response resembling that of helminth-like infections. The probiotic-
induced response in infants at high risk for allergic diseases was characterised by an 
increase in plasma IL-10, total IgE, and CRP levels, without induction of an 
allergen-specific IgE response.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Simplified illustration of the immunological effects of probiotics. Probiotic 
bacteria stimulate innate immunity, as seen in increased plasma CRP levels. Increased 
plasma CRP level at age 6 months was associated with reduced risk for eczema at age 2. 
Probiotic bacteria stimulate Th1 and Th2 immunity via their effect on APCs. Different 
probiotic strains had differing immunostimulatory effects, and effects of probiotic 
bacteria seem to be modulated by the host. The probiotic mixture raised plasma total 
IgE, IL-10, and CRP levels, without induction of an allergen-specific IgE. The beneficial 
immunomodulatory effects of probiotic bacteria in infants resemble immune profiles that 
are characteristic for chronic low-grade inflammation. 
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